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Abstract
Despite a rise in the number of studies looking at the relationship of psychosocial factors
(coping style, personality type, and social support) on HIV/AIDS severity, there remains a lack
of conclusive answers about the specific association between these factors. This study used a
meta-analytic method of analysis to address these issues in the post anti-retroviral treatment
modality world. A systematic search of major psychology and medical computerized databases
led to 110 studies used in the meta-analysis. Social support was found to have the strongest
relationship with HIV progression. Structural social support had greater protective effect on HIV
progression than functional social support. A significant relationship between coping type and
HIV severity was found, with a greater protective benefit seen in studies that utilized CD4 count
as the outcome variable. Positive coping had a beneficial effect on HIV progression while
passive and negative coping had a detrimental effect on disease progression. Among studies of
personality, a weak relationship was found between personality type and HIV severity. In
conclusion, the meta-analytical review found significant associations between psychosocial
factors and HIV severity that could be used to refine individual treatment plans for people living
with HIV/AIDS.
Keywords: Psychoneuroimmunology, HIV/AIDS, social support, coping, personality
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The Association of Psychosocial Factors on HIV/AIDS Disease Progression

There are approximately 34 million individuals living with HIV and 30 million people
who have died of AIDS-related causes since the first case was found (UNAIDS, 2012). Despite
the advancements in medical technology that help treat the disease, only 8 million individuals
living with HIV have access to antiretroviral therapy (ARV), leaving a large amount of
individuals without medication. Thus, it is of utmost importance to identify the psychosocial
factors that affect disease progression so individuals can better their health outcomes through a
complementary model of healing.
The purpose of this thesis was to examine the results of previous empirical studies that
analyzed the association between psychosocial factors and HIV/AIDS progression using a metaanalytic approach. Specifically this paper examined the correlations of the psychosocial factors
of personality (Five-Factor Model: neuroticism, openness to engagement, extraversion,
agreeableness, and conscientiousness), coping type (positive, passive, or negative), and social
support type (functional or structural) on the dependent variables of CD4 count and viral load.
The first aim identified the nature of the relationship between the five-factor model of
personality and the progression of HIV as measured by CD4 count and viral load. The second
aim of the study, analyzed the relationship between HIV-seropositive individuals’ coping type
and progression of HIV as measured by CD4 count and viral load. The third aim of the study
examined the relationship of type of social support and progression of HIV as measured by CD4
count and viral load. The following sections provided a composite view of the psychosocial
factors and discussed how these variables relate to health and immunity of HIV-seropositive
individuals. The results from examining the nature of the associations of the psychosocial factors

PSYCHOSOCIAL ASSOCIATIONS ON HIV DISEASE PROGRESSION

5

on progression in this study have a tremendous impact on comprehensive mind-body
individualized treatment plans for HIV+ individuals in order to improve their survival and wellbeing.
Human immunodeficiency virus virology
Human immunodeficiency virus (HIV), the clinical precursor to acquired immunodeficiency
syndrome (AIDS), is disease affecting the immune system of infected individuals that makes the
individual more vulnerable to potentially fatal opportunistic infections and cancer (Basic
Information about HIV and AIDS, 2012). AIDS is clinically defined by either a CD4+ T cell
count of below 200 cells per µL or the presence of diseases associated with the syndrome such as
pneumocystis pneumonia, esophageal candidiasis, Kaposi’s sarcoma, and AIDS related dementia
(AIDS-PubMed Health, 2012). The virus is potentially transmitted by three main ways: sexual
contact with an infected individual, exposure to infected fluids, and vertical transmission (in
order of frequency) (Basic Information about HIV and AIDS, 2012).
HIV functions through infection of the immune system, specifically the CD4+ T cells,
macrophages, and dendritic cells (Alimonti, Ball, & Fowke, 2003). As viral replication occurs
more rapidly CD4+ T cell counts of the infected individual drop, a marker of disease progression
and severity. The normal CD4 count of a HIV-seronegative individual is 1,000 cells as opposed
to that of 200 cells or less of an individual with AIDS (Osmond, 1998). In the current study the
construct of CD4 counts was used as the dependent variable in measurement of HIV progression.
Viral load is another measurement used to measure the severity of the virus. It is a calculation of
the amount RNA copies per milliliter of blood plasma. Although, CD4 counts and viral load are
similar concepts in assessing progression and severity of HIV/AIDS they are useful in different
aspects of treatment. CD4 counts are measures of immunocompromise useful in determine risk
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for opportunistic infections, stage of disease, prognosis, and whether or not to being
antiretroviral therapy (ART). Viral load measurement is more useful in determine the rate of
disease progression and for ART (CD4 Monitoring and Viral Load Testing, 2011). A low CD4
count combined with a high viral load is indicative of progression, severity, and an increased risk
of contracting opportunistic diseases. In the current study the construct of viral load was used as
the dependent variable in measurement of HIV progression.
Psychoneuroimmunology
In the last few decades etiologies of disease have changed from purely biological to a
comprehensive model, marking the beginning of the field of psychoneuroimmunology. The field
of psychoneuroimmunology seeks to take an interdisciplinary approach to looking at the
interaction between the nervous and immune systems with the psychological. One of the main
theories of the field is the Engel’s biopsychosocial model. This model proposes that the etiology
of disease is based on a reciprocal determinism triad of biology, social factors, and psychology
(Engel, 1977). This means that one’s emotions, cognitions, behaviors, interpersonal relations,
and environment affect the severity and progression of a disease as opposed to solely one’s
biology. Another important theory to the field is the stress immunity health model (SIH), which
seeks to understand how stress impacts one’s immunity and thus lead to negative health
consequences (Keller, Shiflett, Schleifer, & Bartlett, 1994). Biologically, glucocorticoids such
cortisol are released in response to stress acting as an immunosuppressant and increase HIV virus
reproduction (Cupps & Fauci, 1982).
Stress as understood with the SIH model has a direct link to adverse health consequences.
Since, stress is increased or decreased by personality type, coping style, and/or social support it
is important to analyze these mediating factors as well. Stress is difficult to operationalize
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however Taylor defines the construct as “a negative emotional-experience accompanied by
predictable biochemical, physiological, cognitive, and behavioral changes that are directed
toward altering the stressful event or accommodating to its effects” (Taylor, 1999, p. 198). This
wide definition includes the environmental variables and individual physiological events that
include personality and social supports. The level of stress can be measured psychologically
through stress scales or through physiological measures of blood pressure or galvanic skin
response. Although, stress is not being directly analyzed in this meta-analysis it is indirectly
associated with each of the psychosocial factors measured. For example, an association exists
between the five-factor model personality trait of openness to experience and stress regulation. A
study of 73 individuals analyzed the impact that openness had on regulation of an acute
laboratory stressor. Researchers found that individuals who scored high on openness had greater
stress resilience and less likely to develop adverse health effects such as increase in blood
pressure activity or negative affect. Individuals who scored low on openness were found to be
more vulnerable to the effects of stress such as poor sleep quality, increase in respiratory sinus
arrhythmia and increase in blood pressure (Williams, Rau, Cribbet, & Gunn, 2009). Overall, it is
important to note the way in which stress negatively impacts the health in order to understand the
results of this study. Stress exists as a mediating variable for the three psychosocial factors
analyzed in this study. Since it does exist as mediating variable this is important in the
interpretation of the results.
Chronic Disease
Chronic diseases have a biological and psychological effect on the individual. Chronic
diseases are defined as being persistent or having long-lasting effects for more than three months
(Chronic Disease, 2012). The most common examples are arthritis, cancer, cardiovascular
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disease, diabetes, and HIV/AIDS. Chronic disease has psychological effects with diagnosis,
symptoms, medication adherence, stigma and long-term effects requiring adjustment in many
different aspects of one’s life. Research has identified five categories of adjustment to chronic
disease: mastery of disease related adaptive tasks, preservation of functional status, quality of
life, low negative affect, and psychological disorders (Stanton, Collins, Sworowski, 2001).
Positive adjustment within these five categories for the purpose of this study would indicate high
levels of social support, positive coping, and thus slower HIV/AIDS disease progression.
Stress plays an important factor in the etiology, prognosis, and severity of chronic
disease. The effect of stressors on infectious disease outcomes has been tested through
vaccination responses, viral challenge, and reactivation of latent viruses. In Cohen’s viral
challenge research, 420 healthy individuals were inoculated with a type of cold virus under
controlled conditions and then were measured daily for infections symptoms. Cohen found that
higher stress (measured through amount of stressful life events, perceived stress, and negative
affect) predicted greater susceptibility to the virus, increase in symptoms, and lower immune
system functioning (Cohen, Tyrrell, & Smith, 1991). A similar association between lower
immune system functioning and higher amount of life stressors was found in a study of 68
patients with malignant melanoma (Fawzy et al., 1993). Cancer patients with greater selfreported severe life stressors were associated with a greater chance of relapsing. In a follow-up
study patients participated in a six-week structured psychiatric group intervention focusing on
stress coping interventions. The researchers found that the adverse health outcomes caused by
severe life stressors seen in the previous study were not present but rather the patients had
improved survival rates and greater immune functioning. Studies looking at the effect of stress
on immunological functioning of chronically ill patients can be applied to HIV-seropositive
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individuals. For the purpose of this study stress is not a distinct independent variable but rather
implicitly tied to the independent variables of personality, coping type, and social support.
Five-Factor Model of Personality
Personality is defined as set of unique characteristics an individual possesses that
influences one’s behaviors, emotions, motivations, and cognitions (Schacter, Gilbert, & Wegner,
2010). The specific operationalized definition of personality used in this study is the big five
personality traits measured by the revised NEO Personality Inventory (NEO PI-R). The five
personality traits measured are agreeableness, conscientiousness, extraversion, neuroticism, and
openness to experience, with six facets as part of each trait (Costa & McCrae, 1992). Costa and
McCrae’s Five Factor Model of personality was chosen in this study as it is one of the leading
approaches to measuring personality. The NEO PI-R is high in validity in comparison to the
MBTI, MMPI, and Self-Directed Search (Costa & McCrae, 1992). The internal consistency of
the NEO PI-R for each of the domains ranges from a Cronbach’s alpha score from .89 to .93
(McCrae & Costa, 2010). The test retest reliability of the NEO PI-R over a six year period is N =
.83, E = .82, O = .83, A = .63, and C = .79 (McCrae & Costa, 2010).
Neuroticism. According to the Five-Factor Model neuroticism is the tendency to
negative emotions, such depression, anxiety, or anger (Matthews & Deary, 1998). The facets on
the NEO PI-R are anxiety, hostility, depression, self-consciousness, impulsiveness, and
vulnerability to stress. Individuals who are high in neuroticism are more vulnerable to stress and
have a lower tolerance for stress (Norris, Larsen, & Cacioppos, 2007). Individuals high in
neuroticism are more likely to be emotionally reactive, interpret their environment as
threatening, and be more likely to develop depression (Matthews & Deary, 1998). All of the
characteristics of an individual high in neuroticism point to the individual perceiving more stress,
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which has adverse effects on one’s health. One study found high neuroticism was positively
associated with perceive stress and negative emotion in response to an acute stressor (Penley &
Tomaka, 2002).
However there are mixed findings in terms of a conclusive connection between
neuroticism and negative health outcomes (Ironson et al., 2008). A link between high
neuroticism and poorer health has been found with chronic renal insufficiency (Christensen et
al., 2002), mortality (Wilson et al., 2004), and with cancer and coronary heart disease (Eysenck,
1993). However, some studies have found a protective effect with high neuroticism in terms of
mortality (Weiss & Costa, 2005) and myocardial infection (Korten et al., 1999).
Similarly, mixed findings have been found regarding the association of neuroticism and
HIV progression. In a study of 104 HIV-seropositive individuals found that neuroticism scores
from the NEO-PI-R were not significantly associated with a change in viral load over time but
there was a significant association with a faster decrease of CD4 cells (Ironson et al., 2008). In
the same study lower neuroticism (N) was found to be protective and slow progression of the
disease when combined with high extraversion (E), openness (O), or conscientiousness (C).
Another study looked at the effect of neuroticism on amount of negative disease symptoms
reported. The study found that the HIV-seropositive individuals who scored high in neuroticism
were more likely to complain and report disease symptoms. However the somatic complaints did
not translate to significant measurable differences in severity or progression, as measured
through CD4 counts and viral load (Johnson & Neilands, 2007). One hypothesis why
neuroticism has not been conclusively associated with negative health outcomes is the symptom
perception hypothesis. This hypothesis states that individuals who are high in neuroticism are
more likely to have somatic complaints but this does not necessarily reflect actual negative
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health or increased mortality (Costa, 1987). Thus it is important to note the methodology of
studies of neuroticisms and HIV severity and progression whether the measurement of severity
of what is patient reported or not. Neuroticism is hypothesized to have a weak negative
relationship to the outcome variables. This was predicted due to the weak association of
neuroticism and HIV progression found in the literature review and the symptom perception
hypothesis. As the level of neuroticism increased a faster disease progression was predicted as
indicated by higher viral loads and lower CD4 counts.
Extraversion. According to the Five-Factor Model extraversion is characterized by
tendency towards the company of others, assertiveness, and positive emotion. In contrast,
introverts are marked by their need for less social engagement and activity, deliberate choices,
and quietness. A moderate score would be an individual who is energetic but distant or lethargic
but friendly (McCrae et al., 1986). The facets of extraversion on the NEO PI-R are warmth,
gregariousness, assertiveness, activity, excitement seeking, and positive emotion.
The trait of extraversion has been found to be protective against negative health
outcomes, although many studies have not found a significant association. Individuals who were
high in extraversion rated their health as higher than those low in extraversion (Williams,
O’Brien & Colder, 2004). With extraversion’s association to mortality, only two studies have
found a significant protective effect (Shipley, Weiss, Der, Taylor, & Deary, 2007). Low
extraversion scores have been seen with individuals with chronic diseases such as chronic fatigue
(Nater, Jones, Lin, Maloney, Reeves, & Heim, 2010), cancer patients (Cardenal, Cerezo,
Martinez, Ortiz-Tallo, & Blanca, 2012), and renal failure (Kidachi, Kikuchi, Nishizawa, Hirum,
& Kaneko, 2007).
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Although research regarding the trait extraversion and health outcomes may be mixed,
the trait may play more of a significant role in HIV+ individual’s disease progression. This may
be explained by the direct connection between extraversion and social support. In a study of 104
HIV-seropositive individuals the role of the extraversion and its facets was examined in its
relation to changes in CD4 and viral load counts. Ironson found that extraversion’s facets of
assertiveness, positive emotion, and gregariousness were significantly associated with slower
disease progression (Ironson et al., 2008). In a study of 96 individuals examining the prospective
association of affect on HIV disease progression looked specifically at the facet of assertiveness.
The researchers found that individuals with high scores on assertiveness are more likely to seek
the support they need thus leading to more positive health outcomes (Leserman et al., 2002).
Moskowitz analyzed the association of positive affect on HIV disease progression among 407
HIV+ San Francisco men. He found that positive emotions were significantly linked to slower
disease progression (Moskowitz, 2003). Research of 177 HIV+ patients over a period of two
years found that individuals who scored low in optimism loose CD4 cells 1.55 times faster than
individuals who score on scales of optimism (Ironson et al., 2005). Similarly, in a study looking
at the role of dispositional optimism and HIV progression in a cohort of 412 HIV+ individuals
low scores of optimism were correlated to a higher viral load and thus faster disease progression
(Milam, Richardson, Marks, Kemper, & McCuthchan, 2004). Optimists are more likely to adopt
positive coping strategies than passive or negative styles (Ironson et al., 2005). Extroverted
individuals are more likely to experience social support as they have a larger social network than
introverted individuals. Larger network sizes predict slower disease progression over a five-year
period (Patterson et al., 1996). Positive affect, an aspect of positive coping, predicts lower
mortality in a study of 407 HIV-seropositive men over a three-year study period (Moskowitz,
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2003). The trait of extraversion is interlinked to the two other psychosocial factors measured,
coping style and social support, in relation to HIV/AIDS progression and thus was hypothesized
to be one of the strongest associations. The association of extraversion on both of the outcome
measurements was predicted to be greater than the association between the outcome variables
and the other personality traits (neuroticism, openness to experience, agreeableness, and
conscientiousness). As the level of extraversion increased a slower progression was predicted as
indicated by lower viral loads and higher CD4 counts.
Openness to Experience. According to the Five-Factor Model openness to experience
characterizes individuals as sensation seeking and willingly appreciative of their perceived
experiences for themselves. The openness facets on the NEO-PR-I are fantasy, aesthetics,
feelings, actions, ideas, and values. Individuals with high scores of openness to experience are
more likely to have an active imagination, high curiosity, attentive to inner emotions, and
preference for variety (McCrae & John, 1992). An individual who scores low in openness are
more likely to be conventional, traditional in perspective and behavior, favor routine, and
traditional religiosity (McCrae & John, 1992).
There are mixed findings regarding the correlation between openness and health
outcomes. Openness has been found to positively affect stress responses through predicting
lower negative affect and lower cortisol response (Schneider, Rench, Lyons, & Riffle, 2012).
Another study conducted in a cohort of 97 undergraduates looked at the association of NEO-PI-R
personality traits when experiencing the acute stressor of public speaking. The study found that
individuals who scored high on the NEO-PI-R’s openness scale reported lower perceived amount
of stress in response to acute stressor task (Penley & Tomaka, 2002). A number of studies have
found a significant relationship between negative self-rated health and low scores on openness
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trait on the NEO-PI-R (Goodwin & Engstrom, 2002). However, high scores in openness may
still be slightly negative in terms of social support and coping; these individuals are more likely
to be highly sensitive to feelings and may have difficulties relating to others (McCrae, 1993). In
terms of the association between chronic disease severity and openness there has been very few
studies conducted. A study of 300 asthmatic patients analyzed the relationship between
personality traits and the severity and duration of the disease. They found that the patients who
had high scores on the openness scale also experienced a less severe and shorter version of the
disease than those who had low score openness scores (Fernandes et al., 2005). Furthermore, the
average asthmatic individual in the study had lower openness scores than the average score for
individuals in the general population. This may be due to the finding that individuals who are
low in openness have greater aggregate medical illnesses than those high in openness (Chapman,
Lyness, & Duberstein, 2007). Research regarding the association of low scores openness and
morbidity is weak. In a study of 977 patients with significant coronary artery disease researchers
analyzed if certain facets of openness on the NEO-PI-R predicted mortality. They found a
predictive relationship with mortality with individuals who had low scores in the facets of feeling
and actions (Jonassaint et al., 2007). In looking at the findings of correlations between openness
and health outcomes it is important to recognize the potential confound of education. A slightly
significant association exists between high scores on the scale of openness and greater cognitive
ability and academic performance (Steenland, Henley, & Thun, 2002). A study by the American
Cancer Society of two million people looked at the association of educational status on morality.
The authors found a direct association between lower educational status and negative health
outcomes and mortality. Men who were considered high in educational status lived 4.8 years
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longer and women lived 2.7 years longer than members of the cohort who were considered lower
in educational status.
Although there are lack of studies regarding the association of openness and HIV
progression, the largest study analyzing this association has found a significant association with
slower disease progression as measured by CD4 counts and viral load (Ironson et al., 2008). A
study of 104 HIV-seropositive patients examined the role of the big five personality traits on
their change of CD4 and viral load. They found that patients who scored low on the NEO-PI-R’s
openness domain had a viral load more than three times greater than patients who scored higher
on the openness scale. Furthermore, individuals with low openness scores also had a
significantly decreased CD4 count compared to individuals higher in openness over the four-year
study period. (Ironson et al., 2008). Studies have shown that the relationship between openness
and progression to be weaker than with the other five factor model of personality traits and thus
it was hypothesized to have a weaker association in this study. In the present study, as the level
of openness was predicted to increase a non-significant effect on HIV disease progression was
expected as measured by the CD4 count and viral load outcome measurements.
Agreeableness. According to the Five-Factor Model agreeableness is the tendency to be
sympathetic, cooperative, kind, warm, and considerate (Thompson, 2008). The facets on the
NEO PI-R are trust, straightforwardness, altruism, compliance, modesty, and tender-mindedness
(Costa & McCrae, 1992). Individuals who are low in agreeableness are less concerned with
others’ wellbeing, low in empathy, and have a tendency to be manipulative and skeptical in
social situations (Graziano & Eisenberg, 1997).
The trait of agreeableness is extremely important to psychological wellbeing of an
individual as well as physical health. Agreeableness is considered a predictor of health behavior
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(Botth-Kewley & Vickers, 1994), which can be seen with its significant negative association
with chronic stress (Ebstrup et al., 2011) and its protective effect on mortality with the general
population (Weiss & Costa, 2005) and individuals with chronic diseases (Izdebski, 2007).
Research has shown that agreeableness is associated with faster disease progression with
hypertension (Sutin et al., 2010), ALS (Krampe et al., 2008), and breast cancer (Fisher, 1995).
There are mixed findings regarding the correlation between agreeableness and HIV
progression. A study of 104 HIV-seropositive patients examined the role of the big five
personality traits on their change of CD4 and viral load. They found that patient’s scores on
agreeableness were not significantly related to change in viral load or CD4 count over time
(Ironson et al., 2008). However in a study looking at the relationship between the five-factor
model and immune system functioning in a 66 HIV+ African American females a different result
was found. Using CD4 count as a measure of immunity, they found that agreeableness was found
to be the most significant predictor of CD4 change (Millner, 1998). This significant result can be
largely explained by high significance of the altruism facet of agreeableness in its positive
correlation with CD4 count. Further research needs to be conducted regarding the association of
agreeableness and HIV progression as studies have found either to be the most important
personality trait predictor or completely insignificant. Agreeableness was hypothesized to have
one of the most significant associations among the personality types in regards to disease
progression based on the literature review. It was hypothesized that as the level of agreeableness
increased there would be slower disease progression as indicated by lower viral loads and higher
CD4 counts.
Conscientiousness. According to the Five-Factor Model conscientiousness measures
one’s control, regulation, and direction of impulses (Costa & McCrae, 1992). The facets on the
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NEO-PI-R are competence, order, dutifulness, achievement striving, self-discipline, and
deliberation. An individual high in conscientiousness would be more likely to be exhibit selfcontrol, determined, punctual, reliable, purposeful, and strong willed (Costa & McCrae, 1992).
Individuals who score low in conscientiousness are less motivated in task completion, less driven
by success, and less goal-orientated.
Conscientiousness is considered the most important personality predictor of health
(Christensen et al., 2002). Conscientiousness is considered the most significant psychological
predictor of longevity due to its association with the nine leading causes of mortality (alcohol
use, obesity, drug use, exercise, risky sexual behavior, risky driving, violence, suicide, and
tobacco use) (Friedman & Martin, 2011). Individuals low in conscientiousness during chronic
stress experience greater increase in cortisol making them more susceptible to illness than those
high in conscientiousness (Savic, Knezevic, Damjanovic, Spiric, & Matic, 2012). Individuals
with chronic physical diseases ranging from tuberculosis to diabetes have significantly lower
levels of conscientiousness (Goodwin & Friedman, 2006).
Research has shown that high conscientiousness causes slower HIV disease progression
over time. In a study of 104 HIV-seropositive individuals looking at the role of personality as
measured by the NEO-PI-R and HIV disease progression, high scores on conscientiousness were
associated with slower disease progression. Over the four-year study period, individuals who
scored lowed on the conscientiousness scale experienced an increase in viral load of 1.62 times
greater than individuals high in conscientiousness (Ironson et al., 2008). This study found that
the facet of achievement striving had the strongest association with HIV progression out of all
the facets of conscientiousness (Ironson et al., 2008). Another longitudinal study conducted over
a one-year period with 119 HIV-seropositive patients found that conscientiousness predicts
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disease progression. Individuals who had lower scores on the conscientiousness scale
experienced a yearly average decrease of 27 CD4 cells and mean increase of viral load of 13,00
viral copies (O’Cleirigh, Ironson, Weiss, & Costa, 2007). Conscientiousness was hypothesized to
have the strongest association with HIV progression of all the personality types. It was
hypothesized that as the level of conscientiousness increased slower disease progression would
be seen as indicated by lower viral loads and higher CD4 counts.
Five-Factor Model and HIV Progression. In summary, a paucity of studies exist that
analyze the association of the NEO-PI-R on HIV disease progression. Within the literature
review of the association of neuroticism on disease progression mixed findings exist. Research
has pointed to a weak association with more of significance in the negative change on CD4
counts than viral load measurement (Ironson et al., 2008; Johnson & Neilands, 2007). The direct
relationship of neuroticism on adverse health outcomes in HIV-seropositive individuals is
complicated by the finding that individuals who score high in neuroticism are more likely to
complain about somatic symptoms that do not cause a change in CD4 or viral load (Costa, 1987).
Thus, a weak association on progression was hypothesized. Mixed findings exist within the
literature review on the association of extraversion on HIV progression, however a small
significant result exists. The significance is particularly seen among extraversion’s facets of
positive affect, gregariousness, and assertiveness (Ironson et al., 2008; Leserman et al., 2002;
Moskowitz, 2003). Optimism, a component of extraversion, has been shown to have a protective
effect on progression as measured by CD4 and viral load counts (Milam et al., 2004). Thus,
extraversion was hypothesized to have one of the strongest associations of the personality
variables on disease progression. Furthermore, extraversion’s link to social support and coping
type would play a protective effect within the other aims of this study. Within the literature
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review of the association of openness on disease progression, studies have shown that openness
mediates high stress responses in its ability to lower stress and negative self-rated health. Very
few studies have been conducted looking at the factor of openness on disease progression
(Penley & Tomaka, 2002; Schneider, Rench, Lyons, & Riffle, 2012; Goodwin & Engstrom,
2002). However, studies have shown that due to the fact that individuals who score high in
openness are more affect-sensitive they may also have lower levels of social support and coping
(McCrae & John, 1992). The association of openness on HIV disease progression was
hypothesized to be weak. Mixed findings exist within the literature review on the association of
agreeableness on HIV progression, however a small significant result exists within one study.
Agreeableness’s facet of altruism is significantly linked to slowed HIV disease progression
(Millner, 1998). Despite a lack of studies in the area, the connection of agreeableness to the other
constructs of social support and coping type, agreeableness was hypothesized to be significant
associated to slower HIV disease progression. Conscientiousness is the most researched trait in
its association to HIV disease progression. The majority of studies found a large significance in
its association to slower disease progression, particularly in the facet of achievement striving
(O’Cleirigh, Ironson, Weiss, & Costa, 2007; Ironson et al., 2008). Thus, conscientiousness was
hypothesized to be significantly associated with slowed HIV progression in this study.
Stress & HIV progression
Stress plays a negative role in HIV/AIDS disease progression and is implicitly connected
in psychosocial factors such as personality, coping type, and social support. Researchers have
found similar findings with HIV/AIDS research to that of the association between stress and
adverse health outcomes in patients with chronic disease. Biologically, during period of high
stress there is a decrease in killer lymphocytes amongst HIV seropositive individuals (Leserman
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et al., 1997). In a study of 93 HIV+ men it was found that those who experienced greater life
stressors, as measured in a semi-structured interview, are more likely to progress to AIDS
quicker than those who experience less life stressors (Evans et al., 1997). This study also found
that the risk of early HIV disease progression, as measured by viral load, was doubled with every
severe life stressor experienced per six-month period (Evans et al., 1997). Conversely, in a study
of 63 HIV+ individuals those who reported no severe life stressors over the study period
experienced a smaller decline of CD4 count than those who reported greater life stressors
(Patterson et al., 1995). Another study measured the stressful life events with a modified
Psychiatric Epidemiology Research Interview of 82 seropositive gay men and found a correlation
between higher stressful event scores and faster progression to AIDS, as measured by CD4
counts (Leserman et al., 2000).
Psychological stress is operationalized as the amount that individuals perceive or appraise
that their demands exceed their ability to cope (Taylor, 1999). The Perceived Stress Scale is a
measurement of an individual’s perceived stress in their life with higher scores meaning higher
perceived stress (Cohen & Williamson, 1988). A study of 3,471 individuals analyzed the
association between the NEO Five-Factor Inventory’s categories of personality and amount of
stress perceived as measured by Cohen’s Perceived Stress Scale (PSS). Researchers found a
significant negative association between perceived stress and the traits of extroversion,
agreeableness, and conscientiousness. A significant positive association was found between
neuroticism and perceived stress (Ebstrup, Eplov, Pisinger, & Jorgensen, 2011).
Coping Styles
Coping is defined as an individual’s cognitive or behavioral responses to a subjectively
appraised stressful event (Lazarus & Folkman, 1984). In living with a chronic disease such as
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HIV there are many different stressful aspects such as diagnosis, stigma, side-effects of
treatment, taking a complex medication, symptoms, finances, progression, and identity
(Moskowitz & Wrubel, 2005). The challenge with studying coping is the variety of measurement
and labels for different coping responses. In HIV coping studies COPE and the Ways of Coping
(WOC) scale are most frequently used. COPE measures 14 different types of coping: active
coping, planning, suppression of competing activities, restraint, seeking social support for
instrumental reasons, seeking social support for emotional reasons, positive reinterpretation and
growth, acceptance, turning to religion, focus on and venting of emotions, denial, behavioral
disengagement, and mental disengagement (Carver, Scheier, & Weintraub, 1989). The WOC
measures coping more generally through eight subscales: confrontive, distancing, selfcontrolling, seeking social support, self-blame, escape/avoidance, planful problem solving, and
positive reappraisal (Folkman & Lazarus, 1988).
As evidenced by the large number of subscales on the WOC and COPE, coping is divided
into three main types: appraisal-focused, problem-focused, or emotion-focused (Weiten & Lloyd,
2008). Appraisal-focused or adaptive cognitive strategies are when an individual changes the
way they think, their values, or goals in order to lessen the subjective stress (Weiten & Lloyd,
2008). Problem-focused coping is when the individual deals directly with the cause of their
problem in order to change or eliminate the source of the stressor. The main strategies of
problem-focused are taking control, information seeking, and evaluating the situational options
(Somerfield & McCrae, 2000). Emotion-focused strategies deal with the management and
release of the feelings associated with the stressor. The main strategies of emotion-focused
coping are accepting responsibility or blame, disclaiming, escape-avoidance, exercising selfcontrol, and positive reappraisal (Brannon & Feist, 2009). Within each of these coping strategies
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there are positive and negative approaches and thus for the purpose of this meta-analysis coping
types were grouped into positive, passive, or negative coping type. Coping was analyzed in this
study due to its potential as mediating factor in slowing HIV disease progression.
Positive Coping. Positive coping or also known as adaptive or constructive coping
encompasses a variety of different coping techniques that are all considered to improve
functioning of the individual. Due to the subjective nature of stressors and thus coping, it is
difficult to generalize positive coping strategies. However, positive coping is considered to be
effective coping. Zeidner and Saklofske (1996) found eight criteria that define a coping type as
effective: resolution of the stressful situation, reduction of physiological reactions, reduction of
psychological distress, normative social functioning, return to pre-stress activities, well-being of
self and others affected by the situation, maintaining positive self-esteem, and perceived
effectiveness. Coping strategies that fit Zeidner and Saklofske’s criteria of effectiveness include
positive affect, acceptance, positive reappraisal, or cognitive and behavioral engagement.
Studies have found an association between positive coping strategies and HIV disease
progression. The largest study analyzed the association of psychosocial factors on immune
function in their cohort of 773 HIV-seropositive individuals from four U.S. cities. From the
patient’s interview with a medical professional the researchers were able to measure the positive
coping strategies of positive affect, finding meaning, and optimism. They found that these
positive coping strategies were linked to increases in CD4 counts over the five-year study period
(Ickovics et al., 2006). Another study investigated the role of different coping styles in disease
progression in a cohort of 65 HIV-positive homosexual men. Researchers found that strongest
association with the positive strategy of planful problem solving and disease progression with
increased CD4 counts over an average period of 47 months (Vassend & Esklid, 1998). A small
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study of 20 HIV-seropositive adults examined the role of positive coping strategies on HIV
disease progression. Researchers found a significant association with the positive strategies of
active coping, planning, reinterpretation, growth, and positive thought and higher CD4 counts
(Biswas, 2011). More recently, a two-year long study with a cohort of 177 HIV+ individuals
examined the role of positive and proactive coping on disease progression. They found that
proactive behavior predicted a slower decrease in CD4 counts and lower viral load (Ironson et
al., 2005). Lastly, some aspects of emotional expression are considered to be positive coping
strategies although it is important to recognize that this may not be completely generalizable.
One study facilitated emotional and cognitive processing by having the individual free-write
about HIV/AIDS. The participants who experienced positive coping through this exercise
experienced lower viral load and improved CD4 counts over the two-year period (O’Cleirigh et
al., 2003). In this study positive coping strategies are hypothesized to have one of the most
significant associations with slowed progression based on the literature review. In studies of
positive coping there would be an association with lower viral loads and higher CD4 counts.
Passive Coping. Passive coping is difficult to operationalize due to the subject nature of
stress and coping. Some have defined it in terms of the emotional reactions, others with illness
behaviors, and others the combination (Snow-Turek, Norris, & Tan, 1996). Passive strategies are
characterized by external reliance and/or helplessness (Nicholas et al., 1992). Type C coping is
considered passive coping. Type C is characterized in the extreme by non-expression of emotion,
focus on others’ needs to the exclusion of one’s own (Temoshok, 2004).
Current studies have not found a conclusive link between passive coping strategies and
HIV disease progression. Research has shown that the passing coping strategies of denial
(Goodkin, Fuchs, Feaster, Leeka, & Rishel, 1992), behavioral disengagement, and mental
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disengagement are more predictive of negative effects on immune functioning in HIV+
individuals as opposed to positive coping types (Antoni, Goldstein, Ironson, LaPerriere, Fletcher,
& Schneiderman, 1995). In a study examining the association of avoidant coping on disease
progression in 177 HIV-seropositive individuals, researchers found significant correlation.
Individuals who persistently utilize passive avoidant coping strategies experience a 1.7 times
greater decline in CD4 and six times greater viral load than individuals in the study who utilize
positive coping strategies (Ironson et al., 2005). In meta-analysis of type C coping and HIV
progression, researchers found a significant association with the stage of the disease and disease
progression. Type C coping type is associated with faster HIV progression only with individuals
in the mid-stage of HIV progression with CD4 counts of 200-499. However, with HIV+
individuals in early stages with CD4 counts 500+ it is not significantly associated with faster
HIV progression (Vergis & Mellors, 2000). The passive coping strategies’ effects are cumulative
when a HIV+ individual is also a member of a stigmatized group. For example gay HIV+
individuals who conceal their sexual identity, as an ashamed repressive coping technique, have
an accelerated disease progression in terms of CD4 counts (Wald, Dowling, & Temoshok, 2006).
In this study passive coping strategies were not hypothesized to have the strongest associations
with HIV progression due to the subjective nature of passive coping as evidence by the literature
review. As the number of passive coping strategies increased a non-significant decrease was
predicted in disease progression as seen with increased viral loads and decreased CD4 counts.
Negative Coping. Negative coping or also known as maladaptive coping or non-coping
is considered any strategy that maintains or strengthens the stressor. These techniques may be
effective in reducing stress in the short-term however not significantly effective in the long-term.
Some negative coping strategies include disassociation, sensitization, safety behaviors, anxious
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avoidance, self-medication, and escape. Negative avoidant strategies are associated with
increased psychological distress (Downe-Wambold & Melansen, 1995) and adverse illness
outcomes in chronically ill patients (Heim et al., 1997).
Studies have found an association between negative coping strategies and HIV disease
progression. Research has shown that negative affect such as pessimism is associated with higher
viral load over an 18-month period in a cohort of 412 HIV+ individuals (Milam et al., 2004).
Other components of negative affect include denial and hopelessness. Denial was found to
predict faster CD4 decline (Ironson et al., 1994), faster overall progression to AIDS (Leserman et
al., 2000), and mortality (Ironson et al., 1994). A study of 82 HIV+ homosexual men examined
the impact of hopelessness on disease progression. Researchers found that hopelessness was
linked to an accelerated rate of increase in viral load counts of HIV+ individuals (Leserman et
al., 2000). Negative affect is considered emotional-avoidance and is often correlated with
behavioral escape-avoidance strategies such as drug-use, high-risk sexual behaviors, and alcoholuse (Lazarus & Folkman, 1984). These emotional and behavioral avoidance strategies can further
complicated a HIV+ individual’s health with their interference with antiretroviral regimens
(Ickovics & Chesney, 1997). Studies have found that viral load may be more sensitive to the
adverse effects of negative coping than CD4 levels (Ironson et al., 2005). In this meta-analysis
negative coping strategies was hypothesized to have one of the most significant negative
associations with progression based on the literature review. In studies of negative coping a
negative relationship was predicted as seen by higher viral loads and lower CD4 counts.
Coping Type and HIV Progression. In summary, within the literature review of the
association of positive coping on disease progression a range of findings exist. Studies have
predominately analyzed the effect of positive coping on progression through the measurement of
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CD4 count as opposed to viral load. Studies have found that individuals who practice the positive
coping techniques of positive affect, optimism, finding meaning, planning, problem solving, and
reinterpretation are likely to experience an increase in CD4 count over time (Ickovics et al.,
2006; Vassend & Esklid, 1998; Biwas, 2011). A strong association between positive coping
types and slowed HIV progression is hypothesized. Researchers have not found a conclusive link
between passive coping strategies and HIV disease progression. The passive techniques of
behavioral disengagement, denial, avoidance, and mental disengagement have been linked to
faster disease progression as measured by decreases in CD4 and increases in viral load (Antoni et
al., 1995; Ironson et al., 2005). Due to the subjective nature in operationalizing passive coping, it
was not hypothesized to have a strong association on disease progression. Within the literature
review of the association of negative coping on disease progression, mostly negative associations
exist. The negative coping strategies and affects of pessimism, denial, and hopelessness have
been linked to faster disease progression and measured by decreases in CD4 counts (Milam et
al., 2004; Ironson et al., 1994). Thus, it was hypothesized that a strong negative association
exists between negative coping strategies and disease progression.
Social Support
Social support is operationalized as an interaction in which instrumental, recreational, or
socio-emotional resources are exchanged (Cohen & Syme, 1985) that is considered a positive
moderator for physical diseases, psychological disorders, and stress (Gottlieb, 1985). There are
four main functions of social support: companionship, emotional, informational, and tangible
(Uchino, 2004). Companionship support is the sense of social belonging through the engagement
of shared social activities (Uhino, 2004). Emotional support makes the individual feel valued
through affection, acceptance, concern, empathy, and trust (Langford, Bowsher, Maloney, Lillis,
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1997). Information support involves problem-solving assistance through guidance or advice
(Wills, 1991). Tangible support is concrete assistance through financial assistance or other
services (Heaney & Israel, 2008). This study divided social support into the broad categories of
functional and structural support.
Functional support analyzes the function of people in an individual’s social network
through the four functions of social support mentioned above (Uchino, 2004). A study
conducted with a cohort of 78 seropositive individuals analyzed the relationship between
functional social support and disease progression as measured by viral load and CD4
measurements. Researchers found significant correlations between high levels of functional
social support and high levels of CD4 counts and low viral load levels (Clingerman, 2003). This
strong correlation between high levels of functional support and slower disease progression is
seen in the majority of studies analyzing this relationship. A significant relationship between
functional social support and disease progression was predicted, such that as the level of
functional social support increases there would be slower disease progression as measured by
higher CD4 counts and lower viral load measurements. Functional support was predicted to have
a stronger association with disease progression than structural social support.
Structural support on the other hand looks at the extent to which an individual is
integrated in their social network such as through one’s number of social ties (Wills, 1991). A
study conducted in the United States with a cohort of 414 HIV+ males analyzed the relationship
between network size, a facet of structural support, on CD4 count as a measure of disease
progression. Researchers found a strong association between social support network size and
CD4 count, such that as the size of the network increased CD4 counts increased (Patterson,
Shaw, Semple, Cherner, McCutchan, Atkinson & Grant, 1996). The researchers attributed this to
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the fact that a larger network indicates a high degree of sociability, which may be correlated with
poor health habits. Other studies have found a positive relationship between network size and
structural social support and slower disease progression. A longitudinal study of 36 American
women found a positive association between structural support and HIV progression (Walch,
1995). Researchers found that as the size of the network increased, there was a positive increase
in physical health as evidenced by lower viral load measurements. As evidenced by the
inconsistent findings between structural support and disease progression, it was hypothesized
that the association between structural social support and disease progression would be weaker
than the relationship between functional support and progression. Thus, the structural support
studies were predicted to have a higher average viral load amount and lower CD4 count.
Social support is linked to positive reductions of psychological distress and has a
protective effect on physical health. Low social support is associated with an increased risk of
mortality from physical diseases (Uchino, 2004), while high levels of social support have a
protective effect on mortality (Holt, Smith, & Layton, 2010). Furthermore, individuals with low
levels of all types of social support are more likely to have compromised immune functioning
(Uchino, 2006) and overall health complications (Uchino, 2009). Conversely, high levels of
social support are associated with greater overall immunity (Cohen, Doyle, Skoner, Rabin, &
Gwaltney, 1997), age-related decline (Seeman, Lusignolo, Albert, & Berkman, 2001), viral
susceptibility (VanderPlate, Aral, & Magder, 1988), and faster recovery (Kulik & Mahler, 1993).
Research has found a positive association between high levels of social support and
slower HIV progression. A study conducted in Ethiopia with a cohort of 1,815 HIV+ individuals
analyzed the relationship between social support and CD4 count. Researchers found a positive
association between social support and CD4 gain over the study period (Alemu, Mariam, Tsui,
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Ahmed & Shewamare, 2012). Leserman examined the role social support plays on multiple
measures of HIV progression in 96 HIV+ homosexual men over a nine-year period. Lower
cumulative average social support predicted faster negative disease progression (Leserman et al.,
2002). This is complicated by the fact that diagnosis with AIDS is associated with lower levels
of practical and emotional support from family members (Kelly, Raphael, & Statham, 1996). The
overall inadequate social support causes adverse physiological and psychological consequences
(Leserman et al., 1996). The purpose of this meta-analysis was to examine the less researched
question of what type of social support (functional or structural) is linked to slower HIV disease
progression. It was hypothesized that a significant relationship between both types of social
support and the outcome variables would be seen. Higher levels of both types of social support
would be associated with slower disease progression as evidenced by lower viral loads and
higher CD4 counts. Furthermore, a significant difference between the two types of social support
was predicted in terms of their strength of association with disease progression. Higher levels of
functional social support are predicted to have a stronger association with disease progression
than high levels of structural support.
Current Study
The current study explored the association between the psychosocial factors of
personality, coping type, and social support and HIV/AIDS disease progression. A meta-analytic
methodology was employed in this study due to a wide range of conflicting views in the research
in the last twenty years investigating associations between psychosocial factors and HIV disease
progression (Chida & Vedhara, 2009). Conflicting results may be due to differences in
operationalizing concepts of social support and coping styles. Through the meta-analysis method
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employed in this study it would conclusively answer the nature of the psychosocial associations
on HIV disease progression.
It was hypothesized that a significant association would be found between the five
personality variables and HIV disease progression as measured by viral load and CD4 count. A
significant association would indicate that very high or very low levels of the trait had a
significant effect on the outcome variables and thus disease progression. It was hypothesized that
the association would be the strongest with the personality variables of conscientiousness,
agreeableness, and extraversion in order of strength of hypothesized significance. For the
variables of conscientiousness, agreeableness, and extraversion a negative relationship was
hypothesize, such that as the trait increases, disease progression would decrease (lower viral load
and higher CD4 count).
It was hypothesized that a significant relationship would be found within the variable of
coping and each coping type (negative, passive, and positive) and the outcome variables. In
addition, it was hypothesized that the association would be the strongest with positive and
negative coping. For positive coping, a negative relationship was hypothesized such that as
positive coping increased there would be less disease progression as operationalized by higher
CD4 counts and lower viral load. For negative coping, a positive relationship was hypothesized
such that as negative coping increased there would be greater disease progression as
operationalized by lower CD4 counts and higher viral load.
Lastly, it was hypothesized that a significant relationship would exist between the
variable of social support as well as between each type of social support (structural support and
functional support) and outcome variables. For higher levels of both functional and structural
support, a negative relationship was hypothesized such that there would be less disease
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progression as operationalized by lower viral loads and higher CD4 counts. There would be a
significant difference between structural and functional support in terms of disease progression,
as measured by the outcome variables. High levels of functional support would be more strongly
negatively related to slower disease progression than high levels of structural support.
Method
Study selection
Studies were found through a systematic search of general psychology and medical
computerized databases: PsycINFO and PubMed. The main search keyword strategy was (AIDS
or HIV) AND (psych* or personality or coping or social support or anxiety or social support). In
addition, the reference lists of found publications were reviewed.
Inclusion and exclusion criteria
The criteria for inclusion were: (1) an English language full-length publication in a peerreviewed journal; (2) studies conducted in 1996 to 2013; (3) adult study participants (18 years or
older); (4) outcome variables measured as CD4 count or viral load; (5) if more than one
psychosocial factor or outcome variable were studied then the samples are included separately.
Figure 1 summarizes the results of the systematic search.
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Quality assessment
The quality of each study that met all the selection criteria was assessed. The quality
assessment was based on an existing checklist used in similar health psychology meta-analyses
(Laupacis et al., 1994; von Elm et al., 2007). Articles were assessed on a four-point scale (4 = the
highest quality and 0 = lowest quality). The four criteria were: 1) representative sampling or
random recruitment of participants; 2) outcome variables measured by validated clinical
examinations or instruments; 3) independent variables measured by validated clinical
examinations or instruments; 4) control for possible covariate such as sex, socio-economic status
(SES), race, age, and adherence and use of antiretroviral (ARV). A study was considered high
quality if it met three or more of the quality assessment criteria. The quality scores for each
individual study are displayed in Appendix A. In the entire meta-analysis, 32.51% were
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considered excellent (quality score of four), 54.91% were considered good (quality score of
three), 11.66% were considered fair (quality score of two), and 0.92% were considered poor
(quality score of one).
Data coding
A coding guide was developed for the meta-analysis of the studies to identify information
possible moderating effects and potential directions for future study. Of the 4,632 amount of
articles found in the literature search 110 articles met all the inclusion and exclusion
characteristics and were included in this study. A standardized coding form was used for each
study coding for study information (cohort size, year, location), study methodology (e.g.,
longitudinal) covariates (age, sex, SES, race, ARV usage, sexual orientation, disease status),
outcome measurement (CD4+ lymphocyte count or viral load), psychosocial factor (e.g., coping
type, personality, or social support) and measurement scale, quality assessment score, and effect
size. The complete list of variable is displayed in Appendix C.
Data analyses
All analyses were conducted using the software program Statistical Package for the
Social Sciences (SPSS). For each study the correlation coefficient (r) was calculated as the effect
size. Meta-analytic R was chosen as measure of effect size due to its widespread applicability to
different data types and ease of conversion and computation. In the case where a study did not
include an r effect size one was calculated through a study’s descriptive statistics, t statistics,
tables of counts, and F ratios (Rosenthal, 1991). The meta-analytic procedures were conducted as
recommended by Lipsey (Lipsey & Wilson, 2001). Weighted average effect sizes were
calculated through weighting studies’ effect sizes proportionally with their degrees of freedom
(Rosenthal & DiMatteo, 2001). In this study, each psychosocial category measure (e.g. coping,
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personality) was viewed as a separate construct and thus multiple effect sizes may have been
necessary within one study.
A random-effects model was used in this study’s analysis due to the variability of
distribution of effect sizes within study populations. Heterogeneity was measured in order to
determine the degree of variation within the study outcome variables between studies to see the
inconsistency of studies’ results. It was measured through the calculation of the statistic Q. If the
Q tests had a significant results then the moderating factors were the cause of the variability of
the study.
Due to the nature of the methodology of meta-analysis publication bias was a concern.
Publication bias is the greater likelihood for studies with significant results to be published thus
causing a positive bias within the literature. In order to see the degree to which publication bias
exists within the selected studies the fail-safe N, sensitivity analysis, and the degree of
asymmetry were calculated. The fail-safe N calculates the number of unpublished studies with
non-significant findings necessary to reduce the overall significant effect in the meta-analysis to
be non-significant. A large fail-safe N indicates that is unlikely that publication bias is occurring
and that the effect is represented by a Type I error. A sensitivity analysis is a model used to
measure the likelihood of a study being published according to the characteristics of each study’s
cohort populations (Vevea and Woods, 2005). Lastly, the degree of asymmetry was calculated
with Egger’s unweighted regression asymmetry test (Egger et al., 1997). This test detected
whether the data had an asymmetric funnel shape or not. Asymmetry would mean a positive
result bias due to the relationship of study size and effect size. A positive result bias occurs when
studies are more likely to be published when a significant result is found, thus the selected
studies would have an overall bias towards significant data. An unbiased symmetric funnel plot
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would be funnel shaped due to the data point cloud symmetrically organized around the effect
size of the study population.
Results
Meta-Analytic Procedures
Effect Size. All effect sizes were calculated to compare with Pearson r correlation
coefficient (r) in order to have a common effect size across the studies. Most studies analyzed
provided the value of Pearson’s r. In the case that a study did not provide Pearson’s r it was
calculated using Lipsey and Wilson (2000) equation

ESr = (N Σxi yi – Σ xi Σ yi )/( √( N Σx12 – (N Σxi )2(N Σyi 2 – (N Σyi )2)

(1)

where N is the total sample size for the study and the individual level data for the study are the
variables x and y.
Transformations. Effect sizes were calculated for each individual study for comparison
between the independent variables. Appendix A displays the unweighted effect size for each
study. Each effect size was transformed with the Fisher’s Zr transformation of the Pearson’s r
correlation. This transformation was performed to convert Pearson’s r to the normally distributed
variable Z, which was used for computing confidence intervals.

ESzr = .5 [ln (1+r) – ln (1-r)]

(2)

After Fisher’s transformation the mean unweighted effect sizes were calculated for each
domain analyzed (personality, coping type, and social support) by dividing total effect size by
the n, the number of effect sizes in the domain. The mean unweighted effect size was calculated
for the entire domain and each of the different groups based on the domain’s independent
variable. The mean unweighted effect size were not used in further analysis due to the large
amount of bias seen in these studies as well as low power (Lipsey & Wilson, 2001). Weighted
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mean effect sizes were used instead as they inherently have less bias than unweighted estimates
(Lipsey & Wilson, 2001).
The calculation of mean weighted effect sizes involved many different steps. The first
step was calculating the error for each individual study.

Standard Error = 1/(√N-3)

(3)

Hedge’s states the best method of weighing is through calculating inverse variance weights
(Lipsey & Wilson, 2001). The inverse variance weight (wi) is the inverse of the standard error
for each individual effect size. As advised in Lipsey and Wilson, the following calculations were
made for each domain using SPSS command language.

1.

wi x ES = wes

(4)

2. wi x ES2 = wessq

(5)

3. wi2= wsqi

(6)

From these SPSS calculations the mean weighted effect size and standard error of the mean
effect size, were calculated:

ES = (Σ (w x ES) / Σ w)

(7)

SE = √ (1/ Σ w)

(8)

The mean effect size, standard error of the mean effect size, Z-test for the mean effect
size (9), and 95% confidence intervals (10) were calculated for each group in each domain. For
example in the coping domain, the mean effect size was calculated for: CD4 positive, CD4
passive, CD4 negative, VL positive, VL passive, VL negative, total VL, total CD4, total positive,
total passive, and total negative.

Z = ES / SE

(9)

37

PSYCHOSOCIAL ASSOCIATIONS ON HIV DISEASE PROGRESSION

Lower CI = ES – 1.96 (SE)
Upper CI = ES +1.96 (SE)

(10)

Homogeneity Analysis. Homogeneity analyses were conducted in order to determine
whether the assumption that all the effect sizes were estimating the same population mean was
valid. If homogeneity (Q) were statistically significant then it is rejected, the distribution of
effect sizes in the domain was considered heterogeneous. This means that there was greater
variation between effect sizes than one would predict purely from sampling error (Lipsey &
Wilson, 2001). The formula for Q is:

Q = Σ (wxES2) – [(Σ (wxES)2/( Σw)]

df = k -1

(11)

Q was evaluated using the Chi-Square critical values. A calculated Q that was less than the
critical value for Chi-Square fails to reject the null hypothesis of homogeneity. Heterogeneous
distributions were then used to analyze the excess study variability assuming that the variability
was random and fit the random effects model (Lipsey & Wilson, 2001). For each domain with a
significant Q value, heterogeneous distributions were analyzed in order to examine the difference
between the levels of the independent variables. The variables were considered significant if Qb,
the amount of difference between levels of the variable, was significant at the alpha level (α =
.05). The sum of the individual group Q’s within the domain were used to compute the Qb,

Qwithin = Qgroup1 + Qgroup 2

df = k – j

(12)

Qbetween = Qtotal – Qwithin

df = j – 1

(13)

where k is the number of effect sizes in the domain and j is the number of groups. The mean
effect size, standard error, and confidence intervals were calculated for each group (equation 7,
8, and 10).
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Random Effects Model. A random effects model was used in this meta-analysis due to
the significant total Q measurements, which indicated excess variability across the effect sizes in
the domain due to random differences. The random effects variance component (Vθ) was
calculated from the Q statistic:

Vθ = [Qt - (k – 1)] /[ Σw – (Σw2/ Σw)]

(14)

The random effects variance component (Vθ) was used to calculate the random effects model
weight of each study.

W = 1/ (sei2 + Vθ )

(15)

2

The sei was the standard error calculated including the random variance. Using the random
effects variance component the mean effect size, standard error, confidence intervals, and Q
statistics (Equations 7,8, 10, 11, 12, and 13).
Description of Studies and Effect Sizes Included in the Meta-Analysis
One hundred and eleven studies were included in the three meta-analysis domains
(Appendix A). In the social support domain there were forty-two studies, fourteen in the
personality domain, and fifty-five in the coping type domain. Some studies included multiple
correlations between outcome measurement and the other independent variables and they were
reported independently as a separate case. The 111 studies led to 326 measures of effect size
comparisons (111 in social support, 46 in personality, and 169 in coping). Across the studies and
domains, the total sample size was 50,514 with 4,889 in personality, 22,203 in social support,
and 23,422 in the domain of coping. The range of sample sizes for CD4 counts in the personality
domain was from 24 to 258 participants (M = 107.54, SD = 53.37). The range of sample sizes for
viral load measurements in the personality domain was from 56 to 119 participants (M = 99.29,
SD = 19.89). The range of sample sizes for CD4 counts in the coping domain was from 18 to 871
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participants (M = 129.51, SD = 112.13). The range of sample sizes for viral load measurements
in the coping domain was from 41 to 412 participants (M = 172.14, SD = 123.68). The range of
sample sizes for CD4 counts in the social support domain was from 12 to 3,736 participants (M =
180.73, SD = 394.09). The range of sample sizes for viral load measurements in the social
support domain was from 54 to 3,736 participants (M = 314.63, SD = 912.88). Table 1 displays
the descriptive information for each data set such as the mean unweighted effect sizes and range
of effect size scores.
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Table 1
Descriptive Statistics for Effect Sizes Prior to Meta-Analyses
Group
Social Support

# of Effect Sizes

N

Range

Mean Unweighted ES

CD4 Structural

32

7,799

-.320 to .681

0.042

CD4 Functional

63

9,370

-.610 to .575

0.020

VL Structural

6

4,102

-.247 to .750

0.321

VL Functional

10

932

-.300 to .326

0.052

CD4 Neuroticism

11

1,363

-.131 to .234

0.051

CD4 Extraversion

5

571

-.306 to .138

-0.056

CD4 Openness

4

467

.031 to .260

0.133

CD4 Agreeableness

9

847

-.070 to .328

0.147

CD4 Conscientiousness

10

946

-.157 to .333

0.123

VL Neuroticism

1

104

-

0.001

VL Extraversion

1

104

-

-0.030

VL Openness

1

104

-

-0.025

VL Agreeableness

1

104

-

0.009

VL Conscientiousness

3

279

-.284 to .015

-0.161

CD4 Positive

81

10,644

-.341 to .913

0.114

CD4 Passive

25

2,672

-.340 to .520

0.059

CD4 Negative

27

3,909

-.443 to .439

-0.006

VL Positive

22

3,875

-.209 to .469

0.097

VL Passive

5

721

.167 to .243

0.217

VL Negative

9

1,601

-.180 to .750

0.179

Personality

Coping

Due to the bias inherent in mean unweighted effect sizes, all the effect sizes were
weighted by sample size (Lipsey & Wilson, 2001). Further analyses on the data sets involved

PSYCHOSOCIAL ASSOCIATIONS ON HIV DISEASE PROGRESSION

41

only the mean weighted effect sizes in order to increase the reliability of the findings. Table 2
lists the mean unweighted and weighted effect sizes for each group.
Table 2
Mean Effect Sizes
Group
Social Support

Mean Weighted ES

Mean Unweighted ES

CD4 Structural

0.011

0.042

CD4 Functional

0.028

0.020

VL Structural

0.037

0.321

VL Functional

0.060

0.052

CD4 Neuroticism

0.081

0.051

CD4 Extraversion

-0.122

-0.056

CD4 Openness

0.166

0.133

CD4 Agreeableness

0.106

0.147

CD4 Conscientiousness

0.079

0.123

VL Neuroticism

0.001

0.001

VL Extraversion

-0.030

-0.030

VL Openness

-0.025

-0.025

VL Agreeableness

-0.009

0.009

VL Conscientiousness

-0.141

-0.161

CD4 Positive

0.083

0.114

CD4 Passive

0.044

0.059

CD4 Negative

-0.011

-0.006

VL Positive

0.063

0.097

VL Passive

0.212

0.217

VL Negative

0.173

0.179

Personality

Coping

Analyses of mean weighted effect sizes show that in all the data sets, the viral load
measurements had significantly higher effect sizes than the CD4 effect sizes. In the social
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support data set the functional support type was significantly higher than structural social
support. In the coping data set, the negative coping type had the highest average effect size
followed by passive coping and lastly positive coping. In the personality data set, openness was
significantly higher than the other traits followed by extraversion, agreeableness, neuroticism,
and conscientiousness. In Table 3, the weighted mean effect sizes are displayed as well as
confidence intervals, standard error, and tests of homogeneity. The variable Q analyzed how
heterogeneous the data set was, meaning greater variation between the different effect sizes than
normally predicted from sampling error. A Q score larger than the calculated critical Chi-Square
value indicated that the data was more heterogeneous than one would normally expect and the
hypothesis of homogeneity was rejected. It is also important to note that for a few variables such
as CD4 negative coping and VL conscientiousness the confidence interval (CI) ranged from a
negative to positive integer. This may cause a potential inconsistency in the data set (Lipsey &
Wilson, 2001).
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Table 3
Mean Effect Sizes
Group
Social Support

Mean Weighted ES

SE

95% CI

CD4 Structural

0.011

0.011

0.02 to 0.06

81.88 a

CD4 Functional

0.028

0.010

0.01 to 0.05

209.9 a

VL Structural

0.037

0.016

0.01 to 0.06

72.83 a

VL Functional

0.060

0.033

0.01 to 0.07

17.75 a

CD4 Neuroticism

0.081

0.027

0.03 to 0.13

12.78 a

CD4 Extraversion

-0.122

0.042

-0.21 to -0.04

21.07 a

CD4 Openness

0.166

0.047

0.07 to 0.26

4.48 a

CD4 Agreeableness

0.106

0.03

0.04 to 0.17

15.13 a

CD4 Conscientiousness

0.079

0.03

0.01 to 0.14

23.84 a

VL Neuroticism

0.001

0.10

-0.19 to 0.20

0.001

VL Extraversion

-0.030

0.10

-0.23 to 0.17

0.001

VL Openness

-0.025

0.10

-0.23 to 0.17

-0.003

VL Agreeableness

-0.009

0.10

-0.19 to 0.20

4.138

VL Conscientiousness

-0.141

0.10

-0.34 to 0.05

2.853

CD4 Positive

0.083

0.010

0.06 to 0.10

394.1 a

CD4 Passive

0.044

0.020

0.01 to 0.09

108.0 a

CD4 Negative

-0.011

0.016

-0.04 to 0.02

72.25 a

VL Positive

0.063

0.016

0.03 to 0.09

101.8 a

VL Passive

0.212

0.038

0.14 to 0.29

-0.054

VL Negative

0.173

0.025

0.12 to 0.22

23.38 a

Q

Personality

Coping

a

Hypothesis of homogeneity is rejected at p = 0.05

Random Effects Model. A random effects model analysis was performed on each of the
three domains in order to adjust the sample statistics to include excess variability across the
effect sizes in the domain. By including the excess variability the size of the effect sizes
increased, making it more likely for significant interactions to occur between the independent
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variables. The random effects variance (Vθ) was calculated from the Q statistics for each domain
or the degree to which the domain is heterogeneous. The variables that were considered
significantly heterogeneous were marked in Table 3. In Table 4, the new values for each of the
levels of the independent variable after the analysis was rerun with the random effects variance
component included in the appropriate calculations.
Table 4
Random Variance Component Mean Effect Sizes
Group
Mean Weighted ES
Social Support

SE

95% CI

Q

CD4 Structural

0.044

0.024

-0.01 to 0.09

45.97a

CD4 Functional

0.017

0.021

-0.02 to 0.06

88.25 a

VL Structural

0.302

0.252

-0.19 to 0.80

2.794

VL Functional

0.057

0.252

-0.44 to 0.55

-0.299

CD4

0.083

0.027

0.03 to 0.14

-3.748

VL

-0.066

0.045

-0.15 to 0.02

-4.143

CD4 Positive

0.064

0.023

0.02 to 0.11

98.68

CD4 Passive

0.050

0.043

-0.03 to 0.13

23.70

CD4 Negative

-0.006

0.029

-0.06 to 0.05

30.70

VL Positive

0.072

0.020

0.03 to 0.11

80.39a

VL Passive

0.179

-

-

-119.5

VL Negative

0.122

-

-

35.64a

Personality

Coping

a

Hypothesis of homogeneity is rejected at p = 0.05

Social Support
Interaction of social support and HIV progression. A significant relationship between
social support types and the outcome variables was hypothesized. For higher levels of both
functional support and structural support, a negative relationship was hypothesized such that
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there would be slowed disease progression as operationalized by lower viral loads and higher
CD4 counts. There would also be a significant difference between mean effect sizes of structural
and functional support in terms of disease progression, as measured by the outcome variables.
High levels of functional support would be more strongly negatively related to slower disease
progression than high levels of structural support.
A 2 x 2 ANOVA was performed on this data set in order to test the nature of the
interaction between outcome measurement (CD4 versus viral load) and type of social support
(functional support vs. structural support). The transformed variable (ESzr) was used as the
measure of effect size. Consistent with the hypotheses, there was a significant interaction
between outcome measurement and type of social support seen in the effect sizes, F
(1,107)=5.731, MSe = .056, η2 = .051, p = .018. Effect sizes for studies that utilized CD4 count
as the outcome measurement had significantly higher mean effect sizes measuring functional
support (M = 0.214, SD = 0.227) than structural social support (M = 0.047, SD = 0.204). This
means that with disease progression measured by CD4 cell counts, high levels of functional
support were more important than high levels of structural social support in increasing CD4
counts and thus slower progression. Effect sizes for studies that utilized viral load had
significantly higher mean effect sizes for structural support (M = 0.396, SD = 0.494) than
functional support (M = 0.053, SD = 0.178). This indicated that functional support had a greater
protective effect on disease progression, as there were smaller increases in viral load with
functional support than structural support. These results relate to the hypothesis of which type of
social support had the strongest effect on HIV disease progression.
Effect of outcome measurements. Consistent with the hypothesis, there was a
significant main effect for outcome measurement, F (1,107) = 8.209, MSe = .056, η2 = .071, p =
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.005, such that the outcome measurement, CD4 count (M = 0.301, SD = 0.219) had significantly
higher mean effect sizes than viral load (M = 0.1813, SD = 0.36). This indicated that
measurements of CD4 count had a stronger association between the social support variables and
disease progression than studies that utilized viral load count.
Effect of social support type. Consistent with the hypothesis, there was also a
significant main effect for social support type, F (1, 107) = 7.745, MSe = .056, η2 = .067, p =
.006, such that the effect sizes for structural support (M = 0.1022, SD = 0.2202) were rated
significantly higher than for functional support (M = 0.0257, SD = 0.248). This suggests that the
studies analyzing structural support had a stronger association with the outcome variables than
functional support. These results further answer the hypothesis of which type of social support
had the strongest protective effect on HIV progression.
Potential moderating variables. A correlation matrix was created in order to see if there
were any covariates that may be suppressing the significance of the effect size. The only
significant Pearson correlation with the transformed variable ESzr is age (r(111) = 0.221, p =
0.20).
Sensitivity analyses. Tests of homogeneity were performed on the social support data
set. The calculate Q from both the CD4 and viral load effect size groups was larger than critical
value for Chi-Square (Table 4). Thus, the null hypothesis of homogeneity was retained. This
means that variability across effect sizes exceeded what would be expected based on sampling
error. Heterogeneous distribution analysis was used as a follow up test in order to analyze the
excess between study effect size variability. It assumes that the variability in this data set was
random and fit a random effects model. Among the CD4 set of effect sizes in the personality
data set, the Qw (291.77) was greater than critical Chi-square values, thus a random effects
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model was used. The random effects model assumes that the variability between effect sizes was
due to sampling error in the individual studies and variability in a true population’s effects. The
Qb (0.907) was less than the critical Chi-square value. This means that the variability between
the studies was homogenous and thus excess variation or heterogeneity was not seen among this
group. Among the viral load set of effects the Qw (90.58) was larger than the critical Chi-square
value but the Qb (0.39) was smaller than the critical Chi-square value. Thus, a random effects
model was performed on both groups of data.
Lastly, sensitivity analyses were performed on the data set to analyze the publication
biases inherent in meta-analyses. The fail-safe N for the social support was calculated to be 1,720
additional studies must be found in order to increase the p value for this data set above 0.05. The
Egger’s funnel plot is as a visual plot of publication bias for the data set. The funnel plot for the
social support data set can be seen in Appendix B. The funnel plot can be interpreted as a well
behaved data set. The bottom of the plot is made up of the studies with smaller sample sizes and
spread evenly on both sides of the average effect size. The larger N studies tend towards the
average. This symmetrical funnel does not indicate that publication bias nor small study effects
were seen in this data set.
Personality
Interaction of personality and HIV progression. A significant relationship was
hypothesized between the five personality types and HIV disease progression as measured by
viral load and CD4 count. A significant relationship would indicate that very high or very low
levels of the trait had a significant effect on the outcome variables and thus HIV disease
progression. It was hypothesized that the association would be the strongest with the personality
variables of conscientiousness, agreeableness, and extraversion in order of strength of
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hypothesized significance. For the variables of conscientiousness, agreeableness, and
extraversion a negative relationship was hypothesize, such that as the trait increases, disease
progression would decrease as seen by lower viral load and higher CD4 counts.
A 2 x 5 ANOVA was performed on this data set in order to test the nature of the
interaction between outcome measurement (CD4 vs. viral load) and personality type
(neuroticism, extraversion, openness, agreeableness, and conscientiousness). The weighted
average mean effect size including random variance component was used as the measure of
effect size. Contrary to the hypotheses, mean effect sizes for studies that utilized viral load, there
was a non-significant relationship between outcome measurement and personality type, F (4,6) =
.376, MSe = 35.354, p = .816. Contrary to the hypotheses, mean effect sizes for studies that
utilized CD4 count as their outcome measurement, there was a non-significant relationship
between outcome measurement and personality type, F (4, 34) = 2.006, MSe = 28.523, p = .116.
These non-significant relationships between outcome measurements and personality types
indicate that personality type has a weak effect on disease progression. These results answer the
hypothesis of whether personality had a significant effect on HIV disease progression as
measured by viral load and CD4 counts.
Differences between personality types. LSD and Bonferroni were used as follow up
tests. Contrary to the hypothesis in analyzing the CD4 count studies with LSD, there was a
significant difference between CD4 extraversion (M = -2.87, SD = 8.65) and three of the
personality types: CD4 openness (M = 5.30, SD = 5.01), CD4 Agreeableness (M = 4.70, SD =
4.40), and CD4 conscientiousness (M = 3.82, SD = 5.37). It was hypothesized that extraversion
would be the third strongest personality trait and have a beneficial relationship with HIV
progression. However, based on the follow-up findings extraversion as measured by CD4 counts
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had a detrimental effect on progression. However, after utilizing Bonferroni’s there were not any
significant findings for the CD4 outcome measurements and personality. This suggests a weak
relationship between each of the different personality types and disease progression. These
results answer the hypotheses of which personality type had the strongest beneficial relationship
on disease progression.
In analyzing the mean effect size of the viral load studies with LSD, a few significant
differences between personality types were found. Consistent with the hypotheses, the trait with
the largest beneficial effect on HIV progression was viral load conscientiousness (M = -9.72, SD
= 9.70) followed by viral load extraversion (M = -2.24, SD = 7.41), and viral load openness (M =
-1.87, SD = 7.41) in terms of the size of the decrease of viral load. Consistent with the
hypotheses, conscientiousness and extraversion were predicted to be beneficial on HIV
progression however; openness was not predicted to be beneficial in terms of decrease in viral
load amounts. Both neuroticism (M = 0.075, SD = 7.41) and agreeableness (M = 0.67, SD =
7.41) had a negative effect on HIV progression causing an increase in viral load amounts. This
was partially consistent with the hypotheses, as it was predicted that neuroticism would have a
negative effect on HIV progression however agreeableness was predicted to have a beneficial
effect on viral load amounts. Agreeableness had a larger negative effect on viral load amounts
than neuroticism. The effect conscientiousness had on disease progression was significantly
different than the four other personality traits. In comparing conscientiousness to neuroticism
and agreeableness, one can see that conscientiousness has a stronger beneficial relationship with
disease progression while neuroticism and agreeableness have an adverse relationship with
progression. Conscientiousness has a negative relationship with disease progression as measured
by viral load such that as conscientiousness increases, viral load decreases. However, for
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neuroticism and agreeableness there is a small positive relationship causing a detrimental
relationship with progression such that as the two traits increase, viral load does as well. In
comparing conscientiousness to extraversion and openness, one can see that conscientiousness
has a stronger beneficial effect on HIV progression than the two other variables (extraversion
and openness) as evidenced by lower viral load amounts. As the personality trait with the second
strongest positive effect on HIV progression, viral load extraversion is also significantly different
than viral load agreeableness. This indicates that extraversion has a stronger beneficial
relationship with progression than the adverse relationship of agreeableness on progression as
measured by viral load. Furthermore, this significant difference indicates that conscientiousness
has a stronger negative relationship on progression than extraversion such that an increase in
conscientiousness decreases viral load more so than an increase in extraversion. As the
personality trait with the third strongest positive effect on HIV progression, viral load openness
is also significantly different than viral load agreeableness and conscientiousness. This suggests
that openness has a strong beneficial relationship on disease progression, as openness increases
viral load decreases. However, openness does not have as strong of protective relationship on
progression as conscientiousness, as seen by greater decrease in viral load amounts.
Potential moderating variables. A 2 x 5 ANCOVA was performed on this data set to
test the nature of the interaction between outcome measurements (CD4 versus viral load) and
personality types (neuroticism, extraversion, openness, agreeableness, and conscientiousness)
while controlling for the covariate sexual orientation. No significant covariates existed for CD4
effect sizes that include random variance, however sexual orientation was a significant covariate
for viral load effect sizes including random variance (r = .769, p = 0.043). Thus an ANCOVA
was performed on the weighted mean viral load effect size including random variance. Using
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ANOVA, there was no significant interaction between outcome measurement and personality
type in the random variance weighted mean effect sizes, F (4,6) = .376, MSe = 35.354, p = .816.
Even after controlling for the significant covariant, sexual orientation, there still was a nonsignificant relationship between viral load outcome and personality type F (4,7) = .102, MSe =
95.735, p = .965.
Sensitivity analyses. Tests of homogeneity were performed on the personality data set.
The calculated Q from both the CD4 and viral load effect size groups were larger than the critical
value for Chi-Square (Table 4). Thus, the null hypothesis of homogeneity was retained. This
means that variability across effect sizes exceeded what would be expected based on sampling
error. Heterogeneous distribution analysis was used as a follow up test in order to analyze the
excess between study effect size variability. It assumed that the variability in this data set was
random and fit a random effects model. Among the CD4 set of effect sizes in the personality
data set, the Qb (26.25) and Qw (77.03) were both greater than critical Chi-square values, thus a
random effects model was used. The random effects model assumes that the variability between
effect sizes was due to sampling error in the individual studies and variability in a true
population’s effects. Among the viral load set of effects, the Qb (2.85) and Qw (4.14) were both
less than the critical Chi-square values. This means that the variability between the studies was
homogenous and thus excess variation or heterogeneity was not seen among this group.
Therefore, one can be confident that in studies that utilized viral load as their outcome
measurement that all the effect sizes were similar enough to each other in order to make a
meaningful data set. A meaningful data set is one that varies between studies less than due to
random chance thus the results can be explained.
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Lastly, sensitivity analyses were performed on the data set to analyze the publication
biases inherent in meta-analyses. The fail-safe N for the personality data set was calculated to be
182 additional studies, which must be found in order to increase the p value for this data set
above 0.05. The Egger’s funnel plot is as a visual plot of publication bias for the data set. The
funnel plot for the personality data set can be seen in Appendix B. The funnel plot was
interpreted as an asymmetrical data set. This means that a relationship between treatment effect
and study size may be occurring. It could also signify that there are some instances of publication
bias, which were further reinforced by the low fail-safe N number. The fact that the majority of
the data points exist outside of the positive and negative 3 SD confidence interval lines, can be
potentially interpreted as a heterogeneous data set that may have high instances of publication
bias. It is also important to note the criticism of funnel plots, in that they were able to change
quite dramatically in appearance and interpretation based on the scale of y-axis. Potentially, if
the y-axis variable changes from ES to the weighted mean random variance component effect
size the plot would be interpreted differently. Therefore, due to the large amount of ways in
which one can potentially manipulate the data in an Egger’s plot, the interpretation of the graph
should not be solely analyzed as a predictor of publication bias.
Coping
Interaction of coping and HIV progression. It was hypothesized that a significant
relationship would be found with the overall variable of coping and each coping type (negative,
passive, and positive) and the outcome variables (viral load and CD4). In addition, it was
hypothesized that the association would be the strongest with positive and negative coping. For
positive coping, a negative relationship was hypothesized such that as positive coping increased
there would be less disease progression as operationalized by higher CD4 counts and lower viral
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load. For negative coping, a positive relationship was hypothesized such that as negative coping
increased there would be greater disease progression as operationalized by lower CD4 counts
and higher viral load.
A 2 x 3 ANOVA was performed on this data set in order to test the nature of the
interaction between outcome measurement (CD4 vs. viral load) and coping type (positive coping,
passive coping, and negative coping). The weighted average mean effect size was used as the
measure of effect size. Consistent with the hypothesis, there was a significant interaction
between outcome measurement and coping type, F (2,163) = 3.776, MSe =781.795, η2 = .044, p
= .025. This means that regardless of the coping type, coping has a significant effect on HIV
progression.
Consistent with the hypothesis, in the mean effect sizes for studies that utilized CD4
counts a significant effect was seen on HIV progression among the different coping types, F (2,
130) = 3.449, MSe = 28.156, p = .035. This means that each type of coping was significantly
different to each other in terms of mean effect sizes. Consistent with the hypotheses among the
CD4 count studies, positive coping (M = 10.675, SD = 30.46) had the greatest mean followed by
passive coping (M = 4.58, SD = 24.29) and negative coping (M = -1.5978, SD = 19.20). The
greatest mean effect size means that positive coping had the greatest beneficial effect on HIV
progression through an increase in CD4 counts. With positive coping strategies the rate of CD4
increase is more than twice as large as the rate of increase for passive coping. Negative coping’s
mean effect size is negative thus there it has a detrimental effect on progression, as seen by the
decrease in CD4 count.
However, in the effect sizes for studies that utilized viral load as the outcome
measurement, a non-significant effect was seen on HIV progression among the different coping
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types contrary to the hypothesis F (2, 33) = 1.769, MSe = 35.434, p = .186. Among the viral load
studies, positive coping (M = 10.85, SD = 33.48) was significantly different than passive (M =
30.51, SD = 8.60) and negative coping (M = 30.33, SD = 26.53) in terms of mean effect sizes.
This smaller significant mean effect size means that positive coping has a beneficial effect on
progression through smaller increase in viral load than the two other coping types. Passive and
negative coping do not differ significantly from each other. They both have a negative effect on
HIV progression as measured by increase in viral load amounts. The increase in viral load
amount with negative and passive coping is happening at three times the rate of the increase by
positive coping strategies. These results answer the hypothesis of whether there was a significant
beneficial effect of coping type on HIV disease progression.
Effect of outcome measurements. Consistent with the hypothesis, there was a
significant main effect of outcome measurement, F (1, 163) = 9.658, MSe = 781.795, η2 = .056,
p = .002. Follow up tests were conducted using LSD. The mean effect size for viral load studies
(M = 18.45, SD = 30.58) were rated significantly higher than CD4 count (M = 7.04, SD = 27.69)
in terms of effect sizes. This indicates a stronger association between the coping variables and
disease progression, in the studies that used viral load as the outcome variable than studies that
utilized CD4.
Effect of coping type. Contrary to the hypothesis, there was a non-significant effect of
coping type, F (2, 163) = .464, MSe = 781.795, η2 = .006, p = .630. The non-significant effect of
coping type means that one cannot say which coping type has the strongest effect on HIV
progression over both outcome variables. This non-significant finding is not a large issue, as the
interaction between coping type and outcome measurement, which was significant. The
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significant interaction answers the hypotheses of whether coping has an effect on disease
progression and which type has the largest beneficial effect.
Potential moderating variables. A 2 x 3 ANCOVA was performed on the coping data
set to test the nature of the interaction between outcome measurements (CD4 versus viral load)
and coping types (positive, passive, and negative coping) while controlling for the covariates of
age, sex, and transmission type. A correlation matrix was created to see the correlations between
the covariates and the weighted effect size. Significant correlations were found between the
weighted effect size and the covariates age (r = 0.246, p = 0.001), transmission type (r =-0.237, p
= 0.002), and sex (r = -0.178, p = 0.021). A 2 x 3 ANCOVA was used as a follow up to look at
the interaction between outcome measurements on the coping types while controlling for the
covariates of age, sex, and transmission type.
In the initial ANOVA there was not a significant main effect of coping type F (2, 163) =
.464, MSe = 781.795, η2 = .006, p = .630. After controlling for the set of covariates in the
ANCOVA the type of coping remained insignificant, F (2, 160) = .748, MSe = 716.171, p = .475.
This means that the difference in mean effect size between the three types of coping was still not
significantly different even when controlling for the covariates. Although, it should be noted that
after controlling for the set of three covariates the significance of the difference between the
coping types did improve considerably. The covariate age (p = .011) was the only significant
covariate of the three, thus it was the only one accounting for a significant variance in the
analysis as opposed to sex (p = .218) and transmission type (p = .290).
After controlling for sex, transmission type, and age there still was a significant main
interaction of outcome and coping type F (2,160) = 4.333, MSe = 716.171, p = 0.15. CD4
negative coping effect sizes (estimated marginal means = -1.778, SE = 5.166) were significantly
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less than CD4 passive coping (estimated marginal means = 6.069, SE = 5.383) and CD4 positive
coping (estimated marginal means = 10.291, SE = 3.037). This was a similar finding to the
results mentioned above before controlling for the set of covariates. It means that both positive
and passive coping improve disease progression by an increase in CD4 cell counts while
negative coping has a detrimental effect on progression.
There was a significant main effect of outcome measurement F (1, 160) = 9.827, MSe =
716.171, p = .002. Mean effect sizes of viral load (estimated marginal means = 24.179, SE =
5.491) were significantly higher than that of CD4 effect sizes (estimated marginal means = 4.68,
SE =2.683). This indicates a stronger association between the coping variables and progression,
in the studies that used viral load as the outcome variable than studies that utilized CD4.
Sensitivity analyses. Tests of homogeneity were performed on the coping data set. The
calculated Q from both the CD4 and viral load effect size groups was larger than critical value
for Chi-Square (Table 4). Thus, the null hypothesis of homogeneity was retained. This means
that variability across effect sizes exceed what would be expected based on sampling error.
Heterogeneous distribution analysis was used as a follow up test in order to analyze the excess
between study effect size variability. It assumed that the variability in this data set were random
and fit a random effects model. Among the CD4 set of effect sizes in the personality data set, the
Qb (24.85) and Qw (574.35) were both greater than critical Chi-square values, thus a random
effects model was used. The random effects model assumed that the variability between effect
sizes was due to sampling error in the individual studies and variability in a true population’s
effects. Among the viral load set of effects, the Qb (22.80) and Qw (24.85) were also greater
than the critical Chi-square values. Thus a random effects model was also performed on the viral
load groups.
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Lastly, sensitivity analyses were performed on the data set to analyze the publication
biases inherent in meta-analyses. The fail-safe N for the coping data set was calculated to be
2,970 additional studies must be found in order to increase the p value for this data set above
0.05. This large fail-safe N number means that there were not any power issues and this is
considered a strong data set that it unlikely to have publication bias issues or Type I errors. The
Egger’s funnel plot is as a visual plot of publication bias for the data set. The funnel plot for the
coping data set can be seen in Appendix B. The funnel plot can be interpreted as a well behaved
data set. The bottom of the plot is made up of the studies with smaller sample sizes and spread
evenly on both sides of the average effect size. The larger N studies tend towards the average.
Although this plot is defined as well behaved it does not appear perfectly symmetrical. There is
some variance in the relationship extending beyond the positive and negative three standard
deviation range. Although it remains overall pretty symmetrical this means there may be some
publication bias affecting the data set and coping findings. This may be influencing the nonsignificant finding of coping type in the meta-analysis data set.
Discussion
Summary
This meta-analysis sought to discover the relationship between social support, personality
type, and coping style on HIV severity as assessed by viral load and CD4 cell counts. This study
arises from the issue of purely biomedical treatment modalities for people living with
HIV/AIDS. The idea of making a complementary more effective and individually designed
treatment that incorporates mental health care leads to the question of which psychosocial factors
have the greatest impact on HIV progression, the framework for this study.
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Consistent with the hypothesis, social support was found to significantly effect HIV
progression. This finding supports the hypothesis that there would be a significant relationship
between the social support types (structural support and functional support) and the outcome
variables (CD4 and viral load). In further support of the hypothesis, both functional and
structural social support had a beneficial relationship with HIV progression, as evidenced by
lower viral load amounts and higher CD4 cell counts. However, inconsistent with the hypothesis
the relationship between structural support and the outcome variables was significantly stronger
than the relationship of functional support. This finding may be caused in part by the potential
issue of correlation between the two types of social support. Structural support analyzes the
degree of integration of an individual and size of network while functional support analyzes the
function of the network. Potentially, there may be a threshold with one needing a high amount of
structural support in order for functional support to work properly. Thus, the finding of a larger
significant relationship between structural support than hypothesized with functional support.
Overall, social support had a significant effect on slowing HIV progression over time.
Consistent with the hypothesis, coping was found to significantly effect HIV progression.
This finding supports the hypothesis that there would be a significant relationship between the
coping types (positive coping, passive coping, and negative coping) and the outcome variables
(CD4 and viral load). Partially contrary to the hypothesis, that predicted positive and negative
coping to have the strongest effect on disease progression, the largest effect on progression was
seen with positive coping and passive coping. A non-significant difference was found between
the mean effect sizes of the three coping types analyzed without taking into account the outcome
measurement type. However, when solely analyzing the studies that utilized CD4 count as the
outcome measurement, there was a significant difference between the three different coping
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types. Consistent with the hypothesis, positive coping has the strongest protective benefit on
CD4 counts, such that as an individual increases in their positive coping behaviors CD4 counts
increase. Passive coping similarly has a strong protective benefit on CD4 counts. Consistent with
the hypothesis, negative coping styles have a detrimental effect on CD4 counts, such that as an
individual increases in their negative coping techniques their CD4 decreases. Within the viral
load measurements there is not a significant difference between all three coping types. However
consistent with the hypothesis, a significant difference exists between positive coping and the
other two types (passive and negative coping). Contrary to the hypothesis, there is not a
significant difference between passive and negative coping in terms of viral load, as seen in the
CD4 outcome measurements. Individuals who engage in passive or negative coping types
experience three times increase in viral load than those who engage in positive coping
techniques. This discrepancy between the significance of viral load and CD4 may be due to the
fact that viral load is not as strong and consistent of a predictor as CD4 (Chida et al., 2009).
Furthermore, it is highly correlated with the covariates adherence and ARV usage, which could
further suppress the significance of the data.
Contrary to the hypothesis, an overall non-significant finding was found between
personality and HIV progression in this meta-analysis across both outcome measurements. This
indicates that personality type has a weak effect on HIV disease progression. This finding is
contrary to the hypothesis that there would be a significant association between the outcome
variables and personality type (neuroticism, extraversion, openness to experience, agreeableness,
and conscientiousness). As hypothesized, the association between CD4 count and personality
type was stronger than the association between viral load and personality type. This overall nonsignificant finding between personality and progression indicates that across all the personality
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types there is a weak association. However, on the individual type level some of the personality
types were significantly associated with progression that can be interpreted as trends in the
personality data set. This was seen with the traits: extraversion, conscientiousness, and openness
to experience. As the level of these traits increased, slower disease progression occurred as
measured by lower viral load and CD4 cell counts.
Consistent with the hypothesis, among the studies that have CD4 count as the outcome
variable, the strongest effect on progression was with openness to experience followed by
agreeableness, conscientiousness, extraversion, and neuroticism in order of effect strength.
These findings were slightly different than the hypothesized order of relationship strength
between outcome and personality type. It was hypothesized that conscientiousness,
agreeableness, and extraversion would all have the strongest protective effect on HIV
progression as opposed to the findings of openness, agreeableness, and conscientiousness. There
was a significant difference between extraversion and the openness, agreeableness, and
conscientiousness types. Contrary to the hypothesis, as extraversion increased CD4 counts
decreased. This finding is not seen in the majority of research. Extraversion has been show to
have a protective relationship against negative health outcomes, although this is seen to varying
degrees of significance (Williams et al., 2004). Further analysis of the different facets of
extraversion should be researched in the future in order to understand the complete relationship
between extraversion and CD4 count measurement of HIV progression. The predicted positive
protective relationship that openness, agreeableness, and conscientious would increase as CD4
counts increase was found.
Consistent with the hypothesis, among the studies that have viral load as the outcome
variable, the strongest significant individual trait effect on disease progression was with
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conscientiousness followed by extraversion, openness, neuroticism, and agreeableness in order
of strength of the relationship. This indicates which personality types cause the largest increase
or decrease on viral load amounts. It was predicted that conscientiousness, agreeableness, and
extraversion would have the largest protective effects on HIV progression. Conscientiousness,
extraversion, and openness all have a negative relationship with progression, such that as
individuals score higher on these traits they experience a decrease in viral load amounts. For
agreeableness and neuroticism there was a positive relationship, such that as individuals score
higher on these traits they experience an increase in viral load amounts. The hypothesized
protective relationship of conscientiousness and extraversion was seen in the viral load data.
However, the strong relationship between openness was not predicted. In the literature review
there was a paucity of studies that analyzed the association of openness and HIV severity and
thus the hypothesis was based on studies of other autoimmune diseases generally. Perhaps, the
specific nature of HIV differs from general autoimmune diseases thus making openness more
important within the HIV context.
It is important to note that the personality data within the meta-analysis was the only
category that did not have significant overall findings. This may be attributed to the often-weak
nature of personality as a measure of protective health in the disease context. Potentially, using a
predictive linear regression model the findings of personality may be effective in determining
significance of other proven health benefits such social support. Personality may operate as a
mediator variable between coping and social support type. An individual with a certain
personality type may be more likely to perform protective healthy coping types and social
support thus overall improving their CD4 counts.
Limitations
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There are many limitations inherent to meta-analysis methods that must be taken into
consideration when interpreting the findings. The two main types of limitations that must be
analyzed are the Egger’s unweighted regression asymmetry test and the overall publication
biases. In funnel plots that do not resemble an asymmetrical funnel shape this represents a nonsymmetrical relationship between effect size and sample size on the individual study level. This
asymmetry can indicate a publication bias in the complete data set meaning that study authors
are more likely to submit their studies if they had positive significant results than either null,
non-significant, or negative results. This issue is seen to a small degree among the plots for
coping and social support. The personality data set indicates that larger publication bias issues
exist. This may be the due to the fact that the NEO-PR is a more costly test to administer than
many of the measurements used in the two other data sets which impacts the results to be more
likely be positive due to the positive publication bias effect. Although, it is important to note that
Egger’s plots are liberal visual signifiers of potential symmetry issues. It is also important to note
along side Egger’s plots the fail-safe number, which explains how many non-significant studies
must exist to negate the significance of the findings. For each of the data sets the fail-safe
number is very high, thus making it unlikely that this would affect the findings.
The subgroup analyses and Egger’s funnel plot was done to examine the effect of sample
sizes on findings. Overall, the analysis for social support did not show a stronger relationship in
the studies with larger sample sizes. Normally, studies with larger sample sizes have stronger
relationships because of increased power (Lipsey & Wilson, 2001). However, in the personality
and coping data sets this deviation may be the cause of some non-significant findings in the
analysis. If the correlation between larger sample sizes and stronger relations were found, then in
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those two data sets there would be larger effect sizes. Rather in these two data sets there were
smaller thus weaker effect sizes.
Future Implications
Despite the limitations and biases seen in this meta-analysis, the findings are valuable for
improving HIV/AIDS treatment in a non-clinical way on the individual level. They could serve
as complementary to an ARV regimen as things an individual could incorporate into their
treatment. The results indicate that a psychological component should be seen as a necessary
complement to medical interventions. Based on these findings, a potential community health
program could be created in order to emphasize the protective benefits of social support. This
model would emphasize the different components of functional support in an effort to increase
positive interactions with a larger network. This then would be paired with mental health
workshops for individuals newly diagnosed with HIV in order to emphasize the importance of
positive coping strategies especially in regards to their health. Obviously, these programs would
be difficult to enact on a global level with the large amount of people living with HIV/AIDS.
However, a community mental health program tied to the ARV distribution timeline could easily
be created as a more efficient and potentially doable program. The findings suggest that further
research on the predictive validity of a combined model of psychosocial factors to decrease HIV
severity could be the next step. The significant findings of social support and coping type can be
effectively used in improving customizable individual treatment plans for people living with
HIV/AIDS. The findings from this meta-analysis could be invaluable in the creation of a global
complementary medical and mental health program that reduces HIV severity and slows disease
progression.

PSYCHOSOCIAL ASSOCIATIONS ON HIV DISEASE PROGRESSION

64

PSYCHOSOCIAL ASSOCIATIONS ON HIV DISEASE PROGRESSION

65

References
Note studies with an asterisk have been used in the meta-analysis.

AIDS. (2012, April 30). Retrieved October 24, 2012, from PubMed Health website:
http://www.ncbi.nlm.nih.gov/pubmedhealth.
*Alemu, H., Mariam, D., Tsui, A., Ahmed, S., & Shewamare, A. (2012). Effect of depressive
symptoms and social support on weight and cd4 count increase at hiv clinic in
ethiopia. AIDS Care, 24, 866-876. doi: 10.1080/09540121.2011.648160.
Alimonti, J., Ball, T., & Fowke, K. (2003). Mechanisms of cd4+ t lymphocyte cell death in
human immunodeficiency virus infection and aids. Journal of General Virology, 84,
1649-1661. doi: 10.1099/vir.0.19110-0.
*Antoni, M., Goldstein, D., Ironson, G., LaPerriere, A., Fletcher, M., & Schneiderman, N.
(1995). Coping responses to hiv-1 serostatus notification predict concurrent and
prospective immunological status. Clinical Psychology Psychotherapy, 2, 234-248. doi:
10.1002/cpp.5640020407.
*Anderson, E. (2000). Self-esteem and optimism in men and women infected with hiv. Nursing
Research, 49, 262-271. doi: 10.1097/00006199-200009000-00005
*Ashton, E., Chesney, M., Gore-Felton, M., Koopman, C., O'Shea, C., Maldonado, K.,
Bachmann, J., & Israelski, M. (2002). Social support and maladaptive coping as
predictors of the change in physical health symptoms among persons living with
hiv/aids. AIDS Patient Care & STD's, 19, 587-598. doi: 10.1089/apc.2005.19.587.
*Bakke-Friedland, K. (1999). Relations among death anxiety, intrinsic religiosity, social
support, and hiv disease progression. (Doctoral dissertation).
*Ball, J., Tannenbaum, L., Armistead, L., & Maguen, S. (2002). Coping and hiv infection in
african-american women. Women & Health, 35, 17-36. doi: 10.1300/J013v35n01_02

PSYCHOSOCIAL ASSOCIATIONS ON HIV DISEASE PROGRESSION

66

Basic information about hiv and aids. (2012, April 11). Retrieved October 28, 2012, from
Centers for Disease Control website: http://www.cdc.gov/hiv/topics/basic/index.
*Biggar, H., Forehand, R., Devine, D., Brody, G., Armistead, L., Morse, E., & Simon, P. (1999).
Women who are hiv infected: The role of religious activity in psychosocial
adjustment. AIDS Care, 11, 195-199. doi: 10.1080/09540129948081
*Biswas, U. (2011). Positive thought induction for arresting disease progression: A
hypnotherapeutic application in hiv/aids. Psychology Study, 56, 192-205. doi:
DOI:10.1007/s12646-011-0086-x.
Booth-Kewley, S., & Vickers, R. (1994). Associations between major domains of personality
and health behavior. Journal of Personality, 62, 281-298. doi: 10.1111/j.14676494.1994.tb00298.x
*Bottonari, K., Roberts, J., Ciesla, J., & Hewitt, R. (2005). Life stress and adherence to
antiretroviral therapy among hiv-positive individuals: A preliminary investigation. AIDS
Patient Care & STD's, 19, 719-727. doi: 10.1089/apc.2005.19.719
*Bower, J., Kemeny, M., Taylor, S., & Fahey, J. (1998). Cognitive processing, discovery of
meaning, cd4 decline, and aids-related mortality among bereaved hiv-seropositive men
. Journal of Consulting & Clinical Psychology, 66, 979-986. doi: 10.1037/0022006X.66.6.979
Brannon, L., & Feist, J. (2009). Health psychology. (7th ed., p. 121). Wadsworth Cengage
Learning.
*Brashers, D., Haas, S., Neidig, J., & Rintamaki, L. (2002). Social activism, self-advocacy, and
coping with hiv illness. Journal of Social And Personal Relationships, 19, 113-134. doi:
10.1177/0265407502191006

PSYCHOSOCIAL ASSOCIATIONS ON HIV DISEASE PROGRESSION

67

*Burgoyne, R. (2005). Exploring direction of causation between social support and clinical
outcome for hiv-positive adults in the context of highly active antiretroviral
therapy. AIDS Care, 17, 111-124. doi: 10.1080/09540120412331305179
*Burgoyne, R., & Saunders, D. (2000). Perceived support in newly registered hiv/aids clinic
outpatients. AIDS Care, 12, 643-650. doi: 10.1080/095401200750003815
Cardenal, V., Cerezo, M., Martinez, J., Ortiz-Tallo, M., & Blanca, J. (2012). Personality,
emotions, and coping styles: Predictive value for the evolution of cancer patients. Spanish
Journal of Psychology, 15, 756-767. doi: 10.5209/rev_SJOP.2012.v15.n2.38887
Carver, C., Scheier, M., & Weintraub, J. (1989). Assessing coping strategies: A theoretically
based approach. Journal of Personality and Social Psychology, 56, 267-283. doi:
10.1037/0022-3514.56.2.267.
CD4 Monitoring and Viral Load Testing. (2011, January). HRSA HIV/AIDS Programs. Retrieved
October 28, 2012, from http://hab.hrsa.gov/deliverhivaidscare/clinicalguide11/cg206_cd4_monitoring.html
Chapman, B., Lyness, J., & Duberstein, P. (2007). Personality and medical illness burden among
older adults in primary care. Psychosomatic Medicine, 69, 277-282. doi: 10.1097/
PSY.0b013e3180313975.
Chida, Y., & Vedhara, K. (2009). Adverse psychosocial factors predict poorer prognosis in HIV
disease: A meta-analytic review of prospective investigations. Brain, Behavior, And
Immunity, 23, 434-445. doi: 10.1016/j.bbi.2009.01.013.
Christensen, A. J., Ehlers, S. L., Wiebe, J. S., Moran, P. J., Raichle, K., Ferneyhough, K., &
Lawton, W. J. (2002). Patient personality and mortality: A 4-year prospective

PSYCHOSOCIAL ASSOCIATIONS ON HIV DISEASE PROGRESSION

68

examination of chronic renal insufficiency. Health Psychology, 21, 315-320.
doi:10.1037/0278-6133.21.4.315
Chronic Disease. (2012, August 13). Centers for Disease Control and Prevention. Retrieved
October 28, 2012, from http://www.cdc.gov/chronicdisease/overview
Clingerman, E. (2003). Participation in physical activity by persons living with hiv
disease. Journal of the Association of Nurses in AIDS Care, 14, 59-70. doi:
10.1177/1055329003255284
Cupps, T. & Fauci, A. (1982). Corticosteriod-mediated immunoregulation in man. Immunology
Review, 65, 133-155. In Goodkin, K. & Visser, A.P. (Eds.). Psychoneuroimmunology:
stress, mental disorders, and health (2000) p. 317-356. Washington, D.C.: American
Psychiatric Press, Inc. doi: 10.1111/j.1600-065X.1982.tb00431.x
*Cohen, M., Arad, S., Lorber, M., & Shimon, P. (2007). Psychological distress, life stressors,
and social support in new immigrants with hiv. Behavioral Medicine, 33, 45-54. doi:
10.3200/BMED.33.2.45-54.
Cohen, S., Doyle, W., Skoner, D., Rabin, B., Gwaltney, J. (1997). Social ties and susceptibility
to the common cold. Journal of the American Medical Association, 277, 1940-1944. doi:
10.1001.jama.277.24.1940.
*Cole, S., Kemeny, M., Fahey, J., Zack, J., & Naliboff, B. (2003). Psychological risk factors for
hiv pathogenesis: mediation by the autonomic nervous system. Biological Psychiatry, 54,
1444-1456. doi: 10.1016/S0006-3223(02)01888-7.
Costa, P. (1987). Influence of the normal personality dimension of neuroticism on chest pain
symptoms and coronary artery disease. American Journal of Cardiology, 60,20J–26J. doi:
10.1016/0002-9149(87)90679-5.

PSYCHOSOCIAL ASSOCIATIONS ON HIV DISEASE PROGRESSION

69

Costa, P., McCrae, R. Revised NEO Personality Inventory (NEO-PI-R) and NEO Five-Factor
Inventory (NEO-FFI) Professional Manual. Psychological Assessment Resources, Inc;
Odessa, FL: 1992.
*Dalmida, G., Holstad, M., Diiorio, C., & Laderman, G. (2009). Spiritual well-being, depressive
symptoms, and immune status among women living with hiv/aids. Women & Health, 49,
119-143. doi: 10.1080/03630240902915036
*De la Garza-Mercer, F. (2011). Romantic relationships and immune health in hiv latina and
african american women: How do relationship quality and conflict affect cd4 count over
time? . (Doctoral dissertation).
*Devine, D. (1997). The impact of optimism on psychological and physical functioning among
hiv-infected and noninfected african-american women: Curvilinear effects and the
mediational role of coping. (Doctoral dissertation).
Downe-Wambold, B., & Melanson, P. (1995). A causal model of coping and well-being in
elderly people with arthritis. Journal of Advanced Nursing, 27, 1109-1116. doi:
10.1046/j.1365-2648.1998.00621.x
*Dutile, R. (2004). Multiple psychosocial factors as predictors in the progression of hiv-1 to
aids. (Doctoral dissertation).
Ebstrup, J., Eplov, L., Pisinger, C., & Jorgensen, T. (2011). Association between the Five Factor
personality traits and perceived stress: Is the effect mediated by general selfefficacy? Anxiety, Stress, & Cping, 24, 407-419. doi: 10.1080/10615806.2010.540012
Egger, M., Smith, G.D., Schneider, M., Minder, C. (1997) Bias in meta-analysis detected by a
simple, graphical test. British Medical Journal 315, 629-634. doi:
10.1136/bmj.315.7109.629

PSYCHOSOCIAL ASSOCIATIONS ON HIV DISEASE PROGRESSION

70

*Eisenberger, N., Kemeny, M., & Wyatt, G. (2003). Psychological inhibition and cd4 t-cell
levels in hiv-seropositive women. Journal of Psychosomatic Reseach, 54, 213-224. doi:
10.1016/S0022-3999(02)00473-7.
Engel, G. (1977, April). The need for a new medical model: a challenge for
biomedicine. Science, 196, 129-136. doi: 10.1037/h0089260.
*Erlen, J., Stilley, C., Bender, A., Lewis, M., Garand, L., Kim, Y., Pilkonis, P., & Kitutu, J.
(2011). Personality traits and chronic illness: A comparison of individuals with
psychiatric, coronary heart disease, and hiv/aids diagnoses . Applied Nursing
Research, 24, 74-81. doi: 10.1016/j.apnr.2009.04.006
Evans, D., Leserman, J., Perkins, D., Stern, R., Murphy, C., Zheng, B., Gettes, D., Longmate, J.,
Silva, S., van der Horst, C., Hall, C., Folds, J., Golden, R., Petitto, J. (1997). Severe life
stress as a predictor of early disease progression in HIV infection. American Journal of
Psychiatry, 154:630–634. doi: xxx-xxxx.
Eysenck, H. J. (1993). Prediction of cancer and coronary heart disease mortality by means of a
personality inventory: Results of a 15-year follow-up study. Psychological Reports, 72,
499-516. doi:10.2466/pr0.1993.72.2.499
Fawzy FI, Fawzy NW, Hyun CS, Elashoff R, Guthrie D, Fahey JL, Morton DL. Malignant
melanoma: effects of an early structured psychiatric intervention, coping, and affective
state on recurrence and survival 6 years later. Arch Gen Psychiatry 1993; 50:681–689.
doi: 10.1001/archpsyc.60.1.100.
*Fekete, E., Antoni, M., Duran, R., Stoelb, B., Kumar, M., & Schneiderman, N. (2009).
Disclosing hiv serostatus to family members: Effects on psychological and physiological

PSYCHOSOCIAL ASSOCIATIONS ON HIV DISEASE PROGRESSION

71

health in minority women living with hiv. International Journal of Behavioral
Medicine, 16, 367-376. doi: 10.1007/s12529-009-9041-9
Fernandes, L., Fonseca, J., Rodrigues, J., Vaz, M., Almeida, J., Winck, C., & Barreto, J. (2005).
Personality characteristics of asthma patients. Revista Portuguesa de Pneumologia, 11, 734. doi: xxx-xxxx.
Fisher, S. (1995, January). Personality characteristics and breast cancer (Doctoral dissertation).
Retrieved from Dissertation Abstracts International.
Friedman, H., & Martin, L. (2011). The longevity project: Surprising discoveries for health and
long life from the landmark eight-decade study. (1st ed.). New York, NY: Hudson Street
Press.
Folkman, S., & Lazaurs, R. (1988). Ways of Coping Questionnaire. Palo Alto, CA: Consulting
Psychologists Press.
Global Fact Sheet. (2012, November 20). UNAIDS. Retrieved March 20, 2013, from
www.unaids.org/en/media/unaids/contentassets/documents/epidemiology/2012/gr2012/2
0121120_FactSheet_Global_en.pdf.
Goodkin, K., Fuchs, I., Feaster, D., Leeka, J., & Rishel, D. (1992). Life stressors and coping
style are associated with immune measures in hiv-1 infection: A preliminary
report. International Journal of Psychiatry Medicine, 22, 155-172. doi: 10.2190/BD46F4JD-K8TW-RUFH.
Goodwin, R., & Engstrom, G. (2002). Personality and the perception of health in the general
population. Psychological Medicine, 32, 325-332. doi: 10.1017\S0033291701005104

PSYCHOSOCIAL ASSOCIATIONS ON HIV DISEASE PROGRESSION

72

Goodwin, R., & Friedman, H. (2006). Health status and the five-factor personality traits in
anationally representative sample. Journal of Health Psychology, 11, 643-654. doi:
10.1177/1359105306066610
*Grassi, L., Righi, R., Makoui, S., Sighinolfi, L., Ferri, S., & Ghinelli, F. (1999). Illness
behavior, emotional stress, and psychosocial factors among asymptomatic hiv-infected
patients. Psychotherapy and Psychosomatics, 68, 31-38. doi: 10.1159/000012308
*Greeson, J., Hurwitz, B., Llabre, M., Schneiderman, N., Penedo, F., & Klimas, N. (2008).
Psychological distress, killer lymphocytes and disease severity in hiv/aids. Brain,
Behavior, & Immunity, 22, 901-911. doi: 10.1016/j.bbi.2008.01.001
Graziano, W., & Eisenberg, N. (1997). Agreeableness: A dimension of personality. In R. Hogan,
S. Briggs & J. Johnson (Eds.), Handbook of Personality Psychology. San Diego:
Academic Press.
Heim, E., Valach, M. & Schaffner, L. (1997). Coping and psychosocial adaptation: Longitudinal
effects overtime and stages in breast cancer. Psychosomatic Medicine, 59, 408-418. doi:
xxx-xxxx.
Heaney, C., & Israel, B. (2008). “Social networks and social support”. In Glanz, K., Rimer, B.,
& Viswanath, K.. Health Behavior and Health Education: Theory, Research, and
Practice (4th ed.) San Francisco, CA: Jossey-Bass.
*Hobbs, M. (2010). The characteristics of adherent, black, hiv women: The influence of
spirituality, social support and trust in physician on medication adherence and cd4 cell
count.. (Doctoral dissertation).
Holt-Lunstad, J., Smith, T., & Layton, J. (2010). Social relationships and mortality risk: A metaanalytic review. PLoS Medicine, 7. doi: 10.1371/journal.pmed.1000316

PSYCHOSOCIAL ASSOCIATIONS ON HIV DISEASE PROGRESSION

73

Ickovics, J., & Chesney, M. (1997). Issues regarding antiretroviral treatment for patients with
hiv-1 infection. Journal of the American Medical Association, 278, 1233-1234. doi:
doi:10.1001/jama.1997.03550150038026.
*Ickovics, J., Milan, S., Boland, R., Schoenbaum, E., Schuman, P., Vlahov, D. (2006)
Psychological resources protect health: 5-year survival and immune function among
HIV-infected women from four cities. AIDS , 20: 1851-1860. doi:
10.1080/09540120802537864.
*Igreja, I., Zuroff, D., Koestner, R., Saltaris, C., Brouillette, M., & Lalonde, R. (2000). Social
motives, social support, and distress in gay men differing in hiv status. Journal of
Research in Personality, 34, 287-304. doi: doi:10.1006/jrpe.1999.2277.
*Igreja, I. (1997). Psychosocial variables as predictors of psychological distress and well-being
in gay men with hiv and aids. (Doctoral dissertation).
*Ironson, G., Balbin, E., Stuetzle, R., Fletcher, M., O'Cleirigh, C., Laurenceau, J., Schneiderman,
N., & Solomon, G. (2005). Dispositional optimism and the mechanisms by which it
predicts slower disease progression in hiv: proactive behavior, avoidant coping, and
depression. International Journal of Behavioral Medicine, 12, 86-97. doi:
10.1207/s15327558ijbm1202_6
Ironson G, Friedman A, Klimas N, Antoni M, Fletcher M, LaPerriere A, Simoneau J,
Schneiderman N. (1994). Distress, denial, and low adherence to behavioral interventions
predict faster disease progression in gay men infected with human immunodeficiency
virus. International Journal of Behavioral Medicine, 1, 90–105. doi:
10.1207/s15327558ijbm0101_6

PSYCHOSOCIAL ASSOCIATIONS ON HIV DISEASE PROGRESSION

74

*Ironson, G., & Kremer, H. (2009). Spiritual transformation, psychological well-being, health,
and survival in people with hiv. International Journal of Psychiatry in Medicine, 39, 263281. doi: 10.2190/PM.39.3.d
*Ironson, G., O’Cleirigh, C., Schneiderman, N., Weiss, A., & Costa, P. T. (2008). Personality
and HIV Disease Progression: Role of NEO-PI-R Openness, Extraversion, and Profiles of
Engagement. Psychosomatic medicine, 70, 245–253.
doi:10.1097/PSY.0b013e31816422fc.
*Ironson, G., Stuetzle, R., Ironson, D., Balbin, E., Kremer, H., George, A., Schneiderman, N., &
Fletcher, M. (2011). View of god as benevolent and forgiving or punishing and
judgmental predicts hiv disease progression. Journal of Behavioral Medicine, 34, 414425. doi: 10.1007/s10865-011-9314-z
Izdebski, P. (2007). The role of personality and temperamental factors in breast cancer: A 5-year
prospective examination. Polish Psychological Bulletin, 38, 198-205. doi: xxx-xxxx.
*Johnson, M. O., & Neilands, T. B. (2007). Neuroticism, side effects, and health perceptions
among HIV-infected individuals on antiretroviral medications. Journal Of Clinical
Psychology In Medical Settings, 14, 69-77. doi:10.1007/s10880-007-9056-9
Jonassaint, C., Boyle, S., Williams, R., Mark, D., Siegler, I., & Barefoot, J. (2007). Facets of
openness predict mortality in patients with cardiac disease. Psychosomatic Medicine, 69,
319-322. doi: 10.1097/PSY.0b013e318052e27d
*Kalichman, S., Graham, J., Luke, W., & Austin, J. (2002). Perceptions of health care among
persons living with hiv/aids who are not receiving antiretroviral medications. AIDS
Patient Care & STD's, 16, 233-240. doi: 10.1089/10872910252972285

PSYCHOSOCIAL ASSOCIATIONS ON HIV DISEASE PROGRESSION

75

Kelly B, Raphael B, & Statham D. (1996). A comparison of the psychosocial aspects of AIDS
and cancer-related bereavement. International Journal of Psychiatry Medicine, 26:35–
49. doi: 10.2190/PUWY-N3AL-KK3T-B89L
Keller, S.E, Shiflett, S.C., Schleifer, S.J., & Bartlett, J.A., (1994). Stress, immunity, and health.
In Glaser, R., & Kiecolt-Glaser, J. (Eds). Handbook of human stress and immunity (217244). New York: Academic Press.
Kidachi, R., Kikuchi, A., Nishizawa, Y., Hiruma, T., & Kaneko, S. (2007). Personality types and
coping style in hemodialysis patients. Psychiatry Clinical Neuroscience, 61, 339-347.
doi: 10.1111/j.1440-1819.2007.01716.x
*Koopman, C., Gore-Felton, C., Marouf, F., Butler, L., Field, N., Gill, M., Chen, X., & Israelski,
D. (2000). Relationships of perceived stress to coping, attachment and social support
among hiv-positive persons. AIDS Care, 12, 663-672. doi:
10.1080/095401200750003833
Korten, A. E., Jorm, A. F., Jiao, Z. Z., Letenneur, L. L., Jacomb, P. A., Henderson, A. S., &
Rodgers, B. B. (1999). Health, cognitive, and psychosocial factors as predictors of
mortality in an elderly community sample. Journal Of Epidemiology And Community
Health, 53, 83-88. doi:10.1136/jech.53.2.83
Krampe, H., Bartels, C., Victorson, D., Enders, C., Beaumont, J., Cella, D., & Ehrenreich, H.
(2008). The influence of personality factors on disease progression and health-related
quality of life in people with als. Amyotrophic Lateral Sclerosis and Frontotemporal
Degeneration, 9, 99-107. doi: 10.1080/17482960701875805
*Krikorian, R., Kay, J., & Liang, W. (1995). Emotional distress, coping, and adjustment in
human immunodeficiency virus infection and acquired immune deficiency

PSYCHOSOCIAL ASSOCIATIONS ON HIV DISEASE PROGRESSION

76

syndrome. Journal of Nervous & Mental Disease, 183, 293-298. doi: 10.1097/00005053199505000-00003
Kulik, J. & Mahler, H. (1993). Emotional support as a moderator of adjustment and compliance
after coronary artery bypass surgery: A longitudinal study. Journal of Behavioral
Medicine, 16, 45-64. doi: 10.1007/BF00844754
Langford, C., Bowsher, J., Maloney, J., Lillis, P. (1997). Social support: A conceptual analysis.
Journal of Advanced Nursing, 25, 95-100. doi: 10.1046/j.1365-2648.1997.1997025095.x
Laupacis, A., Wells, G., Richardson, S., Tugwell, P. (1994). Users’ guides to the medical
literature. V. How to use an article about prognosis. Journal of American Medical
Association 272, 234-237. doi:10.1001/jama.1994.03520030076032.
Lazarus, R., & Folkman, S. (1984). Stress, appraisal, and coping. New York: Springer.
*LeGrand, S. (2010). Social support and health outcomes among individuals living with hiv in
the deep south. (Doctoral dissertation).
*Leserman, J., Jackson, E., Petitto, J., Golden, R., Silva, S., Perkins, D., Cai, J., & Folds, J.
(1999). Progression to aids: The effects of stress, depressive symptoms, and social
support. Psychosomatic Medicine, 61, 397-406. doi: xxx-xxxx.
*Leserman, J., Petitto, J., Perkins, D., Folds, J., Golden, R., Evans, D. (1997) Severe stress,
depressive symptoms, and changes in lymphocyte subsets in human immunodeficiency
virus-infected men. Archive of General Psychiatry; 54:279–
85. doi:10.1001/archpsyc.1997.01830150105015.
*Leserman, J., Petitto, J., Golden, R., Gaynes, B., Gu, H., Perkins, D., Silva, S., Folds, J., Evans,
D. (2000). The impact of stressful life events, depression, social support, coping and

PSYCHOSOCIAL ASSOCIATIONS ON HIV DISEASE PROGRESSION

77

cortisol on progression to AIDS. American Journal of Psychiatry;157:1221–1228. doi:
10.1176/appi.ajp.157.8.1221.
*Leserman, J., Petitto, J., Gu, H., Gaynes, B., Barroso, J., Golden, R., Perkins, D., Folds, J., &
Evans, D. (2002). Progression to aids, a clinical aids condition and mortality:
psychosocial and physiological predictors. Psychosomatic Medicine, 32, 1059-1073. doi:
10.1017//S0033291702005949.
Lipsey, M. W., & Wilson, D. B. (2001). Practical meta-analysis. Thousand Oaks: Sage.
*Lucero, T. (1999). An exploration of psychological and psychosocial predictors of long-term
survival of hiv infection in a psychiatric population. (Doctoral dissertation).
*Lutgendorf, S., Antoni, M., Ironson, G., Klimas, N., Kumar, M., Starr, K., McCabe, P., &
Cleven, K. (1997). Cognitive–behavioral stress management decreases dysphoric mood
and herpes simplex virus-type 2 antibody titers in symptomatic hiv-seropositive gay
men. Journal of Consulting Psychology, 65, 31-43. doi: 10.1037/0022-006X.65.1.31
Matthews, G., & Deary, I. (1998). Personality Traits. Cambridge, U.K.: Cambridge University
Press.
McCrae, R. (1993). Openness to Experiences as a basic dimension of personality. Imagination,
Cognition, and Personality, 13, 39-55.doi: 10.2190/H8H6-QYKR-KEU8-GAQ0
McCrae, R., & John, O., (1992). An introduction to the five factor model and its applications.
Journal of Personality, 60, 172-215. doi: DOI: 10.1111/j.1467-6494.1992.tb00970.x
McCrae, R., & Costa, P. (2010). NEO Inventories: Professional manual. Lutz, FL: Psychological
Assessment Resources, Inc.

PSYCHOSOCIAL ASSOCIATIONS ON HIV DISEASE PROGRESSION

78

McCrae, R., Costa, P., & Busch, C. (1986). Evaluating comprehensiveness in personality
systems: The california q-set and the five-factor model. Journal of Personality, 54, 430446. doi: DOI: 10.1111/j.1467-6494.1986.tb00403.x
*McGuffey, L. (2001). Benefit finding, medication adherence, and cortisol as mediators of
spirituality, religiousness, and immune status in hiv-seropositive gay and bisexual men. .
(Doctoral dissertation).
*Milam, J. (2006). Posttraumatic growth and hiv disease progression. Journal of Consulting &
Clinical Psychology, 74, 817-827. doi: 10.1037/0022-006X.74.5.817
*Milam, J., Richardson, J., Marks, G., Kemper, C., & McCuthchan, A. (2004). The roles of
dispositional optimism and pessimism in hiv disease progression. Psychological
Health, 19, 167-181. doi: 10.1080/08870440310001652696
*Miller, G., Kemeny, M., Taylor, S., Cole, S., & Visscher, B. (1997). Social relationships and
immune processes in hiv seropositive gay and bisexual men. Annals of Behavioral
Medicine, 19, 139-151. doi: 10.1007/BF02883331
*Millner, V. (1998, July). Personality domains as predictors of health outcome in hiv-infected
African-american females. (Doctoral dissertation). Retrieved from Dissertation Abstracts
International.
*Moskowitz, J. (2003). Positive affect predicts lower risk of aids mortality. Psychosomatic
Medicine, 65, 620-626. doi: 10.1097/01.PSY.0000073873.74829.23
*Moskowitz, J., & Wrubel, J. (2005). Coping with hiv as a chronic illness: Illness appraisals,
coping, and well-being. Psychology and Health, 20, 509-531. doi: 10.1037/t01151-000
*Mulder, C., Antoni, M., Duivenvoorden, H., & Kauffmann, R. (1995). Active confrontational
coping predicts decreased clinical progression over a one-year period in hiv-infected

PSYCHOSOCIAL ASSOCIATIONS ON HIV DISEASE PROGRESSION

79

homosexual men. Journal of Psychosomatic Reseach, 39, 957-965. doi: 10.1016/00223999(95)00062-3
*Mulder, C., Antoni, M., Emmelkamp, P., & Veugelers, P. (1995). Psychosocial group
intervention and the rate of decline of immunological parameters in asymptomatic hivinfected homosexual men.Psychotherapy and Psychosomatics, 63, 185-192. doi:
10.1159/000288958
*Mulder, C., de Vroome, E., van Griensven, G., Antoni, M., & Sandfort, T. (1999). Avoidance
as a predictor of the biological course of hiv infection over a 7-year period in gay
men. Health Psychology, 18, 107-113. doi: 10.1037/0278-6133.18.2.107
*Nair, K. (2009). Psychological well-being and health related quality of life among a group of
low-income women living with hiv/aids in south africa. Journal of Psychology in
Africa, 19, 517-530. doi: xxx-xxxx.
Nater, U., Jones, J., Lin, J., Maloney, E., Reeves, W., & Heim, C. (2010). Personality features
and personality disorders in chronic fatigue syndrome: A population-based study.
Psychotherapy Psychosomatic, 79, 312-318. doi: 10.1159/000319312.
Nicholas, M., Wilson, P., & Goyen, J. (1992). Comparison of cognitive-behavioral group
treatment and an alternative non-psychological treatment for chronic low back pain. Pain,
48, 339-347. doi: 10.1016/0304-3959(92)90082-M.
Norris, CJ; Larsen, JT; Cacioppo, JT (2007). Neuroticism is associated with larger and more
prolonged electrodermal responses to emotionally evocative pictures.
Psychophysiology 44, 823–826. doi: 10.1111/j.1469-8986.2007.00551.x
*O'Connell-Edwards, C., Jones, D., Forehand, R., & Larkin, K. (2008). Cd4 count and physical
symptoms among urban african american mothers with hiv: An examination of the role of

PSYCHOSOCIAL ASSOCIATIONS ON HIV DISEASE PROGRESSION

80

optimism and depressive symptoms. Journal of Clinical Psychology in Medical
Settings, 15, 322-330. doi: 10.1007/s10880-008-9133-8
*O’Cleirigh, C., Ironson, G., Antoni, M., Fletcher, M., McGuffey, L., Balbin, E., Schneiderman,
N., & Solomon, G. (2003). Emotional expression and depth processing of trauma and
their relation to long-term survival in patients with hiv/aids. Journal of Psychosomatic
Research, 54, 225-235. doi: 10.1016/S0022-3999(02)00524-X
*O'Cleirigh, C., Ironson, G., Weiss, A., & Costa, P. (2007). Conscientiousness predicts disease
progression (cd4 number and viral load) in people living with hiv. Health Psychology, 26,
473-480. doi: 10.1037/0278-6133.26.4.473
*Oppenheimer, M. (2008). The effects of gender, ethnicity and socio-economic status on coping
with hiv . (Doctoral dissertation).
Osmond, D. (1998, May). Epidemiology of Disease Progression in HIV. HIV InSite Gateway to
HIV and AIDS Knowledge. Retrieved October 25, 2012, from
http://hivinsite.ucsf.edu/InSite?page=kb-03-01-04#S4X
*Patterson, T., Semple, S., Temoshok, L., Atkinson, J., McCutchan, J., Straits-Troster, K.,
Chandler, J., Grant, I. (1995). Stress and depressive symptoms prospectively predict
immune change among HIV-seropositive men. Psychiatry;58:299–312. doi: xxx-xxxx.
Patterson, T., Shaw, W., Semple, S., Cherner, M., McCutchan, A., Atkinson, J., & Grant, I.
(1996). Relationship of psychosocial factors to hiv disease progression. Behavioral
Medicine Journal, 18, 30-39. doi: 10.1007/BF02903937
Penley, J., & Tomaka, J. (2002). Associations among the big five, emotional responses, and
coping with acute stress. Personality and Individual Differences, 32, 1215-1228. doi:
10.1016/S0191-8869(01)00087-3

PSYCHOSOCIAL ASSOCIATIONS ON HIV DISEASE PROGRESSION

81

*Ramer, L., Johnson, D., Chan, L., & Barrett, M. (2006). The effect of hiv/aids disease
progression on spirituality and self-transcendence in a multicultural population. Journal
of Transcultural Nursing, 17, 280-289. doi: 10.1177/1043659606288373
*Reed, G., Kemeny, M., Taylor, S., & Visscher, B. (1999). Negative hiv-specific expectancies
and aids-related bereavement as predictors of symptom onset in asymptomatic hivpositive gay men. Health Psychology, 18, 354-363. doi: 10.1037/0278-6133.18.4.354
*Rice, E., Comulada, S., Green, S., Arnold, E., & Rotheram-Borus, M. (2009). Differential
disclosure across social network ties among women living with hiv.AIDS & Behavior, 13,
1253-1261. doi: 10.1007/s10461-009-9554-x
*Robbins, M., Szapocznik, J., Tejeda, M., Samuels, D., Ironson, G., & Antoni, M. (2003). The
protective role of the family and social support network in a sample of hiv-positive
african american women: Results of a pilot study. Journal of Black Psychology, 29, 1737. doi: 10.1177/0095798402239227.
Rosenthal, R., DiMatteo, M.R. (2001). Meta-analysis: recent developments in quantitative
methods for literature reviews. Annual Review of Psychology. 52, 59-82. doi:
10.1146/annurev.psych.52.1.59
Rosenthal, R. (1991). Meta-analytic Procedure For Social Research, 2nd ed. Sage, Newbury Park,
CA.
Savic, D., Knezevic, G., Damjanovic, S., Spiric, Z., & Matic, G. (2012). The role of personality
and traumatic events in cortisol levels--where does ptsd fit in. Psychoendocrinology, 37,
937-947. doi: 10.1016/j.psyneuen.2011.11.001.
Schacter, D. L., Gilbert, D. T., & Wegner, D. M. (2010).Psychology. (2nd ed., p. 468). New
York: Worth Pub.

PSYCHOSOCIAL ASSOCIATIONS ON HIV DISEASE PROGRESSION

82

Schneider, T., Rench, T., Lyons, J., & Riffle, R. (2012). The influence of neuroticism,
extraversion, and openness on stress responses. Stress and Health, 28, 102-110. doi:
10.1002/smi.1409.
Seeman, T., Lusingnolo, T., Albert, M., Berkman, L. (2001). Social relationships, social support,
and patterns of cognitive aging in healthy, high-functioning older adults: MacArthur
studies of successful aging. Health Psychology, 20, 243-255. doi: 10.1037/02786133.20.4.243.
*Segerstrom, S., Taylor, S., Kemeny, M., Reed, G., & Visscher, B. (1996). Causal attributions
predict rate of immune decline in hiv-seropositive gay men.Health Psychology, 15, 485493. doi: 10.1037/0278-6133.15.6.485
Shipley, B., Weiss, A., Der, G., Taylor, M., & Deary, I. (2007). Neuroticism, extraversion, and
mortality in the uk health and lifestyle survey: A 21-year prospective cohort study.
Psychosomatic Medicine, 69, 923-931. doi: 10.1097.PSY.0b013e31815abf83.
Snow-Turek, A., Norris, M., & Tan, G. (1996). Active and passive coping strategies in chronic
pain patients. Pain, 64, 455-462. doi: 10.1016/0304-3959(95)00190-5
*Solano, L., Costa, M., Temoshok, L., Salvati, S., Coda, R., Aiuti, R., Di Sora, F., & D'Offizi, F.
(2002). An emotionally inexpressive (type c) coping style influences hiv disease
progression at six and twelve month follow-ups. Psychology & Health, 17, 641-655. doi:
10.1080/08870440290025830
*Solano, L., Montella, F., Salvati, S., Di Sora, F., Murgia, F., Figa-Talamanca, L., Zoppi, L., &
Lauria, F. (2001). Expression and processing of emotions: Relationships with cd4 levels
in 42 hiv-positive asymptomatic individuals. Psychology & Health, 16, 689-698. doi:
10.1080/08870440108405867.

PSYCHOSOCIAL ASSOCIATIONS ON HIV DISEASE PROGRESSION

83

Solano, L., Costa, M., Salvati, S., Coda, R., Aiuti, F., Mezzaroma, I., Bertini, M. (1993)
Psychological factors and clinical evolution in HIV-1 infection: a longitudinal study.
Journal of Psychosomatic Research. 37, 39–51. doi: 10.1016/0022-3999(93)90122-V
Somerfield, M., & McCrae, R. (2000). Stress and coping research: Methodological challenges,
theoretical advances, and clinical applications. American Psychologist, 55, 620-625. doi:
10.1037/0003-066X.55.6.620.
Stanton, A., Collins, C., & Sworowski, L. (2001). Adjustment to chronic illness: theory and
research. In A. Baum, T. Revenson & J. Singer (Eds.),Handbook of Health
Psychology (pp. 387-403).
Steenland, K., Henley, J., & Thun, M. (2002). All-cause and cause-specific death rates by
educational status for two million people in two American cancer society cohorts, 19591965. American Journal of Epidemiology, 156, 11-21. doi: 10.1093/aje/kwf001.
*Strachan, E., Bennett, W., Russo, J., & Roy-Byrne, P. (2007). Disclosure of hiv status and
sexual orientation independently predicts increased absolute cd4 cell counts over time for
psychiatric patients.Psychosomatic Medicine, 69, 74-80. doi:
10.1097/01.psy.0000249900.34885.46
Sutin, A., Scuteri, A., Lakatta, E., Tarasov, K., Ferucci, L., Costa, P., Schlessinger, D., & Uda,
M. (2010). Trait antagonism and the progression of arterial thickening: women with
antagonistic traits have similar carotid arterial thickness as men. Hypertension, 56, 617622. doi: 10.1161/HYPERTENSIONAHA.110.155317.
Taylor, S.E. (1999). Health psychology. New York: McGraw Hill.
*Tang, H. (2002). Impact of social support and stress on health-related quality of life among
people living with hiv and aids. (Doctoral dissertation).

PSYCHOSOCIAL ASSOCIATIONS ON HIV DISEASE PROGRESSION

84

*Temoshok, L., Waldstein, S., Wald, R., Garzino-Demo, A., Synowski, S., Sun, L., & Wiley, J.
(2008). Type c coping, alexithymia, and heart rate reactivity are associated independently
and differentially with specific immune mechanisms linked to hiv progression. Brain,
Behavior, & Immunity, 22, 781-792. doi: 10.1016/j.bbi.2008.02.003
Temoshok, L. (2004). Type c coping/behavior pattern. In A. Christensen, R. Martin & J. Smyth
(Eds.), Health Psychology. New York: Plenum.
*Theorell, T., Blomkvist, V., Jonsson, H., & Schulman, S. (1995). Social support and the
development of immune function in human immunodeficiency virus
infection. Psychosomatic Medicine, 57, 32-36. doi: xxx-xxxx.
*Thomason, B., Jones, G., McClure, J., & Brantley, P. (1996). Psychosocial co-factors in hiv
illness: An empirically-based model. Psychology & Health, 11, 385-393. doi:
10.1080/08870449608400266
Thompson, E. (2008). Development and validation of an international english big-five minimarkers. Personality and Individual Differences, 45, 542-548. doi:
10.1016/j.paid.2008.06.013.
*Thornton, S., Troop, M., Burgess, A., Button, J., Goodall, R., Flynn, R., Gazzard, B., &
Catalan, J. (2000). The relationship of psychological variables and disease progression
among long-term hiv-infected men. International Journal of STD & AIDS, 11, 734-742.
doi: 10.1258/0956462001915165
*Tomakowsky, J., Lumley, M., Markowitz, N., & Frank, C. (2001). Optimistic explanatory style
and dispositional optimism in hiv-infected men. Journal of Psychosomatic Reseach, 51,
577-587. doi: 10.1016/S0022-3999(01)00249-5

PSYCHOSOCIAL ASSOCIATIONS ON HIV DISEASE PROGRESSION

85

*Trevino, K., Pargament, K., Cotton, S., Leonard, A., Hahn, J., Caprini-Faigin, C., & tsevat, J.
(2010). Religious coping and physiological, psychological, social, and spiritual outcomes
in patients with hiv/aids: Cross-sectional and longitudinal findings. AIDS & Behavior, 14,
379-389. doi: 10.1007/s10461-007-9332-6
Tyrrel, D, Cohen, S., & Smith, A. (1991). Psychological stress and susceptibility to the common
cold. New England Journal of Medicine. 325,606–612. doi:
10.1056/NEJM199108293250903
Uchino, B. (2009). Understanding the links between social support and physical health: A lifespan perspective with emphasis on the separability of perceived and received support.
Perspectives on Psychological Science, 4, 236-255. doi: 10.1111/j.17456924.2009.01122.x
Uchino, B. (2006). Social support and health: A review of physiological processes potentially
underlying links to disease outcomes. Journal of Behavioral Medicine, 29, 377-387. doi:
10.1007/s10865-006-9056-5
Uchino, B. (2004). Social support and physical health: Understanding the health consequences
of relationships. New Have, CT: Yale University Press.
*Ullrich, P., Lutgendorf, S., & Stapleton, J. (2003). Concealment of homosexual identity, social
support and cd4 cell count among hiv-seropositive gay men.Journal of Psychosomatic
Reseach, 54, 205-212. doi: 10.1016/S0022-3999(02)00481-6
VanderPlate, C., Aral, S., & Magder, L. (1988). The relationship among genital herpes simplex
virus, stress, and social support. Health Psychology, 7, 159-168. doi: 10.1037/02786133.7.2.159

PSYCHOSOCIAL ASSOCIATIONS ON HIV DISEASE PROGRESSION

86

*Vassend, O., & Esklid, A. (1998). Psychological distress, coping, and disease progression in
hiv-positive homosexual men. Journal of Health Psychology, 3, 243-257. doi:
10.1177/135910539800300208.
*Vassend, O., Esklid, A., & Halvorsen, R. (1997). Negative affectivity, coping, immune status,
and disease progression in hiv infected individuals. Psychology & Health, 12, 375-388.
doi: 10.1080/08870449708406714
Vergis, E., & Mellors, J. (2000). Natural history of hiv-1 infection. Infectious Disease Clinical
North America,14, 809-816. doi: : 10.1016/S0891-5520%2805%2970135-5
Vevea, J.L., & Woods, C.M. (2005). Publication bias in research synthesis: Sensitivity analysis
using a priori weight functions. Psychological Methods. 10, 428-443. doi: 10.1037/1082989X.10.4.428
von Elm, E., Altman, D., Egger, M., Pocock, S., Gotzche, P., & Vanderbroucke, J. (2008). The
strengthening the reporting of observational studies in epidemiology (strobe) statement:
guidelines for reporting observational studies. Journal of Clinical Epidemiology, 61, 344349. doi: 10.1371/journal.pmed.0040297
*Vosvick, M., Gore-Felton, C., Koopman, C., Thoresen, C., Krumboltz, J., & Spiegel, D. (2002).
Maladaptive coping strategies in relation to quality of life among hiv adults. AIDS &
Behavior, 6, 97-106. doi: 10.1023/A:1014584730432
Walch, S. (1995). The impact of perceived stress and social support on psychological adjustment
and immunological functioning in women with hiv and aids. (Master's thesis).
*Wald, R., Dowling, G., & Temoshok, L. (2006). Coping styles predict immune system
parameters and clinical outcomes in patients with hiv. Retrovirology, 3, 65. doi:
10.1186/1742-4690-3-S1-P65

PSYCHOSOCIAL ASSOCIATIONS ON HIV DISEASE PROGRESSION

87

Weiss, A., & Costa, P. (2005). Domain and Facet Personality Predictors of All-Cause Mortality
Among Medicare Patients Aged 65 to 100. Psychosomatic Medicine, 67, 715-723.
doi:10.1097/01.psy.0000181272.58103.18
Weiten, W., & Lloyd, M. (2008). Psychology applied to modern life. (9th ed.). Wadsworth
Cengage Learning.
Williams, P., O’Brien, C., & Colder, C. (2004). The effects of neuroticism and extraversion on
self-assessed health and health-related cognition. Personality and Individual Differences,
37, 83-94. doi: 10.1016/j.paid.2003.08.001
Williams, P. G., Rau, H. K., Cribbet, M. R., & Gunn, H. E. (2009). Openness to experience and
stress regulation. Journal Of Research In Personality,43, 777-784.
doi:10.1016/j.jrp.2009.06.003
Wills, T. (1991). Social support and interpersonal relationships. Prosocial Behavior, Review of
Personality and Social Psychology, 12, 265-289. doi: xxx-xxxx.
Wilson, R. S., de Leon, C., Bienias, J. L., Evans, D. A., & Bennett, D. A. (2004). Personality and
Mortality in Old Age. The Journals Of Gerontology: Series B: Psychological Sciences
And Social Sciences, 59,110-116. doi:10.1093/gerosnb/59.3.P110
*Woods, T., Antoni, M., Ironson, G., & Kling, D. (1999). Religiosity is associated with affective
status in symptomatic hiv-infected african-american women.Journal of Health
Psychology, 4, 317-326. doi: 10.1177/135910539900400302
Zeidner, M., & Saklofske, D. (1996). Adaptive and maladaptive coping. In M. Zeidner & N.
Endler (Eds.), Handbook of coping: Theory, research, application. 505-531. New York:
Wiley.

88

PSYCHOSOCIAL ASSOCIATIONS ON HIV DISEASE PROGRESSION
Appendix A
Meta-Analysis Coping Studies

#

First
Author

1a

Ironson, G.

2005

1b

Ironson, G.

2005

2

Vassend, O.

2007

3

Cole, S.

1996

4

Patterson, T.

1996

80
41
4

5

Mulder, C.

1995

51

6a

McGuffey, L

2001

55

6b

McGuffey, L

2001

55

6c

McGuffey, L

2001

55

6d

McGuffey, L

2001

7a

Milam, J

7b

Year

N
16
0
16
0
10
4

Adverse psychosocial
factor (measurement)
Negative Coping (COPE)

Covariates
Ag, Rc, Ad,
SES, ARV, Sex
Ag, Rc, Ad,
SES, ARV, Sex

Quality
Score
(0-4)

Effect
Size (r)

CD4

3

0.188

Viral Load

3

0.174

Outcome

Negative Coping (COPE)
Negative Coping
(WOC/EPQ)
Passive Coping (Diagnostic
Interview)

Ag, SES

CD4

2

0.097

Ag, ARV

CD4

2

0.216

Negative Coping (WOC)

Ag, Rc, SES

CD4

2

0

2

0

CD4

2

0.31

CD4

2

-0.29

Viral Load

2

-0.1

Viral Load

2

-0.09

2006

41
2

Positive Coping (LOT-R)

CD4

3

0.07

Milam, J

2006

41
2

Positive Coping (LOT-R)

CD4

3

0.04

7c

Milam, J.

2006

41
2

Positive Coping (LOT-R)

CD4

3

0.03

7d

Milam, J

2006

41
2

Negative Coping (LOT-R)

CD4

3

-0.04

7e

Milam, J

2006

41
2

Negative Coping (LOT-R)

CD4

3

-0.07

7f

Milam, J

2006

41
2

Positive Coping (LOT-R)

Viral Load

3

-0.14

7g

Milam, J

2006

41
2

Positive Coping (LOT-R)

Viral Load

3

-0.06

7h

Milam, J.

2006

41
2

Positive Coping (LOT-R)

Viral Load

3

-0.1

7i

Milam, J

2006

41
2

Negative Coping (LOT-R)

Viral Load

3

0.13

7j

Milam, J

2006

41
2

Negative Coping (LOT-R)

Viral Load

3

0.16

8a

Cole, S.

2003

54

Negative Coping (PANAS)

Viral Load

2

0.75

8b

Cole, S.

2003

54

Negative Coping (PANAS)

Ag, SES, ARV
Ag, Rc, Ad,
SES, Sx, ARV
Ag, Rc, Ad,
SES, Sx, ARV
Ag, Rc, Ad,
SES, Sx, ARV
Ag, Rc, Ad,
SES, Sx, ARV
Ag, Rc, Ad,
SES, ARV, Sex,
Or
Ag, Rc, Ad,
SES, ARV, Sex,
Or
Ag, Rc, Ad,
SES, ARV, Sex,
Or
Ag, Rc, Ad,
SES, ARV, Sex,
Or
Ag, Rc, Ad,
SES, ARV, Sex,
Or
Ag, Rc, Ad,
SES, ARV, Sex,
Or
Ag, Rc, Ad,
SES, ARV, Sex,
Or
Ag, Rc, Ad,
SES, ARV, Sex,
Or
Ag, Rc, Ad,
SES, ARV, Sex,
Or
Ag, Rc, Ad,
SES, ARV, Sex,
Or
Ag, RC, SES,
Or
Ag, RC, SES,
Or

CD4

55

Negative Coping (HCL)
Positive Coping
(IWORSHIP)
Positive Coping
(IWORSHIP)
Positive Coping
(IWORSHIP)
Positive Coping
(IWORSHIP)

Viral Load

2

-0.18
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9c

Eisenberger,
N.
Eisenberger,
N.
Eisenberger,
N.

10a

Tomakowsk
y, J.

2001

78

Positive Coping (LOT)

10b

Tomakowsk
y, J.

2001

Negative Coping (PANAS)

11

Thornton, S.

2000

Positive Coping (COPE)

Ag, SES, ARV

CD4

3

0

12

Vassend, O.

1997

78
14
7
10
7

Ag, Rc, SES,Sx,
Or
Ag, Rc, SES,Sx,
Or
Ag, Rc, SES,Sx,
Or
Ag, Ys, Ad,
SES, ARV, Sx,
Or
Ag, Rc, Ys, Ad,
SES, ARV, Sx,
Or

Passive Coping (WOC)

Ag, SES

CD4

2

0.097

13a

Mulder, C.

1995

51

Positive Coping (HCL)

Ag, SES, ARV

CD4

3

0.166

13b

Mulder, C.

1995

Passive Coping (HCL)

3

0

Woods, T.

1999

Positive Coping (COPE)

CD4

2

0.139

14b

1999

Positive Coping (COPE)

CD4

2

0.19

15

Woods, T.
Lutgendorf,
S.

Ag, SES, ARV
Ag, Rc, ARV,
Or
Ag, Rc, ARV,
Or

CD4

14a

51
10
6
10
6

1997

22

Positive Coping (COPE)

Ag, Rc

CD4

4

-0.11

16

Solano,L.

2001

Positive Coping (RA)

2

0.28

Greeson, J.

2008

Passive Coping (IES)

CD4

3

-0.18

17b

Greeson, J.

2008

Passive Coping (IES)

Ag, TT, Sx, Or
Ag, Rc, Ys,
ARV, Sx
Ag, Rc, Ys,
ARV, Sx

CD4

17a

42
20
0
20
0

Viral Load

3

0.22

18a

Mulder, C.

1995

18

Positive Coping (COPE)

Rc, SES, Or

CD4

3

0.007

18a

Mulder, C.

1995

CD4

3

0.52

19a

Solano, L.

2002

CD4

3

0.201

19b

Solano, L.

2002

Passive Coping (COPE)
Positive Coping
(Temoshok)
Passive Coping
(Temoshok)

CD4

3

0.271

20a

Ramer, L.

2006

CD4

3

0.152

9a
9b

2003

61

Positive Coping (LIWC)

2003

61

Passive Coping (LIWC)

2003

61

Negative Coping (LIWC)

CD4

1

-0.01

CD4

1

-0.34

CD4

1

-0.12

CD4

2

-0.05

CD4

2

-0.14

20b

Ramer, L.

2006

18
20
0
20
0
42
0
42
0

Positive Coping (STS)

Rc, SES, Or
Ag, TT, Ys, Sx,
Or
Ag, TT, Ys, Sx,
Or
Ag, Rc, SES,
Sx, Or
Ag, Rc, SES,
Sx, Or

CD4

3

-0.044

21

1999

72

Negative Coping (NHAPS)

Ag, Rc, Or

CD4

4

0.024

1996

82

Positive Coping (NHAPS)

Ag, Rc, Or

CD4

4

0.122

22b

Reed,G.
Segerstrom,
S.
Segerstrom,
S.

1996

82

Ag, Rc, Or

CD4

4

0.037

23a

Bower, J.

1998

40

Ag,ARV, Or

CD4

3

-0.04

23b

Bower, J.

1998

40

Positive Coping (NHAPS)
Positive Coping (Cognitive
Processing)
Positive Coping (Discovery
of Meaning)

Ag,ARV, Or

CD4

3

-0.015

24a

Vassend, O.

1998

62

Positive Coping (WCCL)

Ag, Ys, Or

CD4

3

-0.286

22a

Positive Coping (QOL)

24b

Vassend, O.

1998

62

Positive Coping (WCCL)

Ag, Ys, Or

CD4

3

-0.21

24c

Vassend, O.

1998

62

Positive Coping (WCCL)

Ag, Ys, Or

CD4

3

-0.316

24d

Vassend, O.

1998

62

Positive Coping (WCCL)

Ag, Ys, Or

CD4

3

-0.341

24e

Vassend, O.

1998

62

Positive Coping (WCCL)

Ag, Ys, Or

CD4

3

-0.07

24f

Vassend, O.

1998

62

Negative Coping (WCCL)

Ag, Ys, Or

CD4

3

0.027

24g

Vassend, O.

1998

62

Negative Coping (WCCL)

Ag, Ys, Or

CD4

3

-0.332

25a

O'Cleirigh,

2003

41

Positive Coping (Depth of

Ag, Rc, TT, Ys,

CD4

3

0.495
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C.

Processing)

25b

O'Cleirigh,
C.

2003

94

Positive Coping (Depth of
Processing)

25c

O'Cleirigh,
C.

2003

41

Positive Coping (Positive
Emotional Expression)

25d

O'Cleirigh,
C.

2003

94

Positive Coping (Positive
Emotional Expression)

25e

O'Cleirigh,
C.

2003

41

Negative Coping (Negative
Emotional Expression)

25f

O'Cleirigh,
C.

2003

94

Negative Coping (Negative
Emotional Expression)

25g

O'Cleirigh,
C.

2003

41

Positive Coping (Depth of
Processing)

25h

O'Cleirigh,
C.

2003

94

Positive Coping (Depth of
Processing)

25i

O'Cleirigh,
C.

2003

41

Positive Coping (Positive
Emotional Expression)

25j

O'Cleirigh,
C.

2003

94

Positive Coping (Positive
Emotional Expression)

25k

O'Cleirigh,
C.

2003

41

Negative Coping (Negative
Emotional Expression)

25l

O'Cleirigh,
C.

2003

94

Negative Coping (negative
Emotional Expression)

26a

Ashton, E.

2005

65

Passive Coping (COPE)

26b

Ashton, E.

2005

65

Passive Coping (COPE)

26c

Ashton, E.

2005

65

Passive Coping (COPE)

26d

Ashton, E.

2005

65

Passive Coping (COPE)

26e

Ashton, E.

2005

65

Negative Coping (COPE)

26f

Ashton, E.

2005

65

Negative Coping (COPE)

27

2000

28c

Leserman, J.
Temoshok,
L.
Temoshok,
L.
Temoshok,
L.

2008

82
27
3
27
3
27
3

Passive Coping (COPE)
Positive Coping
(Temoshok)
Negative Coping
(Temoshok)
Positive Coping
(Temoshok)

28d

Temoshok,

2008

27

Negative Coping

28a
28b

2008
2008

Ad, SES, ARV,
Sx, Or
Ag, Rc, TT, Ys,
Ad, SES, ARV,
Sx, Or
Ag, Rc, TT, Ys,
Ad, SES, ARV,
Sx, Or
Ag, Rc, TT, Ys,
Ad, SES, ARV,
Sx, Or
Ag, Rc, TT, Ys,
Ad, SES, ARV,
Sx, Or
Ag, Rc, TT, Ys,
Ad, SES, ARV,
Sx, Or
Ag, Rc, TT, Ys,
Ad, SES, ARV,
Sx, Or
Ag, Rc, TT, Ys,
Ad, SES, ARV,
Sx, Or
Ag, Rc, TT, Ys,
Ad, SES, ARV,
Sx, Or
Ag, Rc, TT, Ys,
Ad, SES, ARV,
Sx, Or
Ag, Rc, TT, Ys,
Ad, SES, ARV,
Sx, Or
Ag, Rc, TT, Ys,
Ad, SES, ARV,
Sx, Or
Ag, Rc, Ad,
SES, ARV, Sx,
Or
Ag, Rc, Ad,
SES, ARV, Sx,
Or
Ag, Rc, Ad,
SES, ARV, Sx,
Or
Ag, Rc, Ad,
SES, ARV, Sx,
Or
Ag, Rc, Ad,
SES, ARV, Sx,
Or
Ag, Rc, Ad,
SES, ARV, Sx,
Or
Ag, Rc, Ys, Ad,
ARV, Or

CD4

3

0.125

CD4

3

0.495

CD4

3

0.171

CD4

3

0.099

CD4

3

0.001

Viral Load

3

0.224

Viral Load

3

0.077

Viral Load

3

0.469

Viral Load

3

0.315

Viral Load

3

0.056

Viral Load

3

0.036

CD4

4

-0.07

CD4

4

-0.07

CD4

4

0.01

CD4

4

0.01

CD4

4

-0.08

CD4

4

-0.05

CD4

4

0.257

Ag, Rc, Sx

CD4

4

-0.134

Ag, Rc, Sx

CD4

4

-0.152

Ag, Rc, Sx

Viral Load

4

0.165

Ag, Rc, Sx

Viral Load

4

0.179
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L.

3

(Temoshok)

29

Mulder, C.

1999

18
1

30a

Ironson, G.

2006

10
0

Positive Coping (LOT)

30b

Ironson, G.

2006

10
0

Positive Coping (Proactive
Coping)

30c

Ironson, G.

2006

10
0

Positive Coping
(Spirituality)

30d

Ironson, G.

2006

10
0

Passive Coping (COPE)

30e

Ironson, G.

2006

10
0

Positive Coping (LOT)

30f

Ironson, G.

2006

10
0

Positive Coping (Proactive
Coping)

30g

Ironson, G.

2006

10
0

Positive Coping (COPE)

30h

Ironson, G.
O'ConnellEdwar

2006

10
0

Passive Coping (LOT)

Dalmida, G.
Dalmida,
SG.

2009

31
32a
32b
32c
32d
32e

Dalmida, G.
Dalmida,
SG.

2008

2009
2009
2009

32f

Dalmida, G.
Dalmida,
SG.

2009
2009

33a

Ironson, G.

2011

33b

Ironson, G.

2011

33c

Ironson, G.

2011

33d

Ironson, G.

2011

33e

Ironson, G.

2011

33f

Ironson, G.

2011

33g

Ironson, G.

2011

33h

Ironson, G.

2011

33i

Ironson, G.

2011

33j

Ironson, G.

2011

99
12
9
12
9
12
9
12
9
12
9
12
9
10
1
10
1
10
1
10
1
10
1
10
1
10
1
10
1
10
1
10
1

Passive Coping (UCL)

Positive Coping (LOT)
Positive Coping (SWB)
Positive Coping (SWB)
Positive Coping (SWB)
Positive Coping (SWB)
Positive Coping (SWB)
Positive Coping (SWB)
Positive Coping (COPE)
Positive Coping (GIS)
Positive Coping (LOT)
Passive Coping (COPE)
Negative Coping (GIS)
Positive Coping (COPE)
Positive Coping (GIS)
Positive Coping (LOT)
Passive Coping (COPE)
Negative Coping (GIS)

Ag, Ys, SES, Or
Ag, Rc, TT, Ys,
Ad, SES, ARV,
Sx, Or
Ag, Rc, TT, Ys,
Ad, SES, ARV,
Sx, Or
Ag, Rc, TT, Ys,
Ad, SES, ARV,
Sx, Or
Ag, Rc, TT, Ys,
Ad, SES, ARV,
Sx, Or
Ag, Rc, TT, Ys,
Ad, SES, ARV,
Sx, Or
Ag, Rc, TT, Ys,
Ad, SES, ARV,
Sx, Or
Ag, Rc, TT, Ys,
Ad, SES, ARV,
Sx, Or
Ag, Rc, TT, Ys,
Ad, SES, ARV,
Sx, Or

CD4

4

-0.15

CD4

4

0.158

CD4

4

0.258

CD4

4

0.301

CD4

4

0.2

Viral Load

4

0.153

Viral Load

4

0.045

Viral Load

4

0.293

Viral Load

4

0.243

Ag, Rc, SES
Ag, Rc, Ad,
ARV
Ag, Rc, Ad,
ARV
Ag, Rc, Ad,
ARV
Ag, Rc, Ad,
ARV
Ag, Rc, Ad,
ARV
Ag, Rc, Ad,
ARV
Ag, Rc, Ad,
ARV, Sex
Ag, Rc, Ad,
ARV, Sex
Ag, Rc, Ad,
ARV, Sex
Ag, Rc, Ad,
ARV, Sex
Ag, Rc, Ad,
ARV, Sex
Ag, Rc, Ad,
ARV, Sex
Ag, Rc, Ad,
ARV, Sex
Ag, Rc, Ad,
ARV, Sex
Ag, Rc, Ad,
ARV, Sex
Ag, Rc, Ad,
ARV, Sex

CD4

4

-0.119

CD4

4

0.19

CD4

4

0.19

CD4

4

0.128

CD4

4

0.128

CD4

4

0.174

CD4

4

0.174

CD4

4

0.26

CD4

4

0.215

CD4

4

0.16

CD4

4

0.2

CD4

4

-0.443

Viral Load

4

0.05

Viral Load

4

-0.209

Viral Load

4

0.15

Viral Load

4

0.24

Viral Load

4

0.309
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34a

Trevino, K.

2007

34b

Trevino, K.

2007

34c

Trevino, K.

2007

34d

Trevino, K.

2007

35a

Miller, G.

1997

35b

Miller, G.

1997

35c

Miller, G.

1997

36a

Ironson, G.

2005

36b

Ironson, G.

2005

36c

Ironson, G.

2005

36d

Ironson, G.

2005

36e

Ironson, G.

2005

36f

Ironson, G.

2005

36g

2005
2008

37l

Ironson, G.
Oppenheime
r, M.
Oppenheime
r, M.
Oppenheime
r, M.
Oppenheime
r, M.
Oppenheime
r, M.
Oppenheime
r, M.
Oppenheime
r, M.
Oppenheime
r, M.
Oppenheime
r, M.
Oppenheime
r, M.
Oppenheime
r, M.
Oppenheime
r, M.

32
9
32
9
32
9
32
9
20
5
20
5
20
5
16
0
17
7
16
0
16
0
17
7
16
0
16
0

38a

Positive Coping (FACIT)

Ag, Ys, Sx,Or

CD4

3

-0.04

Positive Coping (PUREL)

Ag, Ys, Sx,Or

CD4

3

-0.027

Positive Coping (FACIT)

Ag, Ys, Sx,Or

Viral Load

3

0.12

Positive Coping (PUREL)

Viral Load

3

0.089

CD4

4

-0.03

CD4

4

0.12

CD4

4

0.09

CD4

3

0.254

CD4

3

0.19

CD4

3

-0.139

Viral Load

3

0.048

Viral Load

3

-0.001

Viral Load

3

0.213

Passive Coping (COPE)

Ag, Ys, Sx,Or
Ag, Rc, Ad,
ARV, Or
Ag, Rc, Ad,
ARV, Or
Ag, Rc, Ad,
ARV, Or
Ag, Rc, Ad,
SES, ARV, Sx
Ag, Rc, Ad,
SES, ARV, Sx
Ag, Rc, Ad,
SES, ARV, Sx
Ag, Rc, Ad,
SES, ARV, Sx
Ag, Rc, Ad,
SES, ARV, Sx
Ag, Rc, Ad,
SES, ARV, Sx
Ag, Rc, Ad,
SES, ARV, Sx

Viral Load

3

0.167

78

Positive Coping (WOC)

Rc, SES, Sx

CD4

3

0.368

2008

78

Positive Coping (WOC)

Rc, SES, Sx

CD4

3

0.534

2008

78

Positive Coping (WOC)

Rc, SES, Sx

CD4

3

0.673

2008

78

Positive Coping (WOC)

Rc, SES, Sx

CD4

3

0.243

2008

78

Positive Coping (WOC)

Rc, SES, Sx

CD4

3

0.913

2008

78

Positive Coping (WOC)

Rc, SES, Sx

CD4

3

0.072

2008

78

Positive Coping (WOC)

Rc, SES, Sx

CD4

3

0.097

2008

78

Positive Coping (WOC)

Rc, SES, Sx

CD4

3

0.501

2008

78

Positive Coping (WOC)

Rc, SES, Sx

CD4

3

0.739

2008

78

Negative Coping (WOC)

Rc, SES, Sx

CD4

3

0.439

2008

78

Negative Coping (WOC)

Rc, SES, Sx

CD4

3

0.257

2008

78

Negative Coping (WOC)

CD4

3

0.026

Vosvick, M.

2002

14
1

Passive Coping (COPE)

CD4

4

-0.13

38b

Vosvick, M.

2002

14
1

Passive Coping (COPE)

CD4

4

-0.15

38c

Vosvick, M.

2002

14
1

Passive Coping (COPE)

Rc, SES, Sx
Ag, Rc, Ad,
SES< ARV, Sx,
Or
Ag, Rc, Ad,
SES< ARV, Sx,
Or
Ag, Rc, Ad,
SES< ARV, Sx,
Or

CD4

4

-0.14

38d

Vosvick, M.

2002

14

Negative Coping (COPE)

Ag, Rc, Ad,

CD4

4

-0.05

37a
37b
37c
37d
37e
37f
37g
37h
37i
37j
37k

Negative Coping (POMS)
Negative Coping (POMS)
Negative Coping (POMS)
Positive Coping (COPE)
Positive Coping (LOT)
Passive Coping (COPE)
Positive Coping (COPE)
Positive Coping (LOT)
Passive Coping (COPE)
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38e

Vosvick, M.

2002

14
1

Negative Coping (COPE)

SES< ARV, Sx,
Or
Ag, Rc, Ad,
SES< ARV, Sx,
Or

39

Devine, D.

1997

64

Positive Coping (LOT)

Ag, SES

CD4

4

-0.16

40a

Ball, J.

2002

99

Positive Coping (COPE)

Ag, SES

CD4

3

0.114

40b

2002

99

Positive Coping (COPE)

Ag, SES

CD4

3

-0.005

1999

97

Positive Coping (IRM)

Ag, Rc, SES, Or

CD4

3

-0.197

1999

Ag, Rc, SES, Or
Ag, Rc, Ys,
SES, Sx, Or
Ag, Rc, Ys,
SES, Sx, Or
Ag, Rc, Ys,
SES, Sx, Or

CD4

3

-0.023

2000

CD4

4

0.316

CD4

4

0.285

CD4

4

-0.021

3

-0.214

Ironson, G.

2009

CD4

4

0.198

44b

Ironson, G.

2009

Viral Load

4

0.202

45

Ickovics, J.

2006

Positive Coping (POMS)

CD4

4

-0.18

46a

Thornton, S.

2000

Positive Coping (COPE)

Ag, SES, ARV

CD4

3

0.269

46b

2000

Positive Coping (COPE)

Ag, SES, ARV

CD4

3

0.162

1995

57

Positive Coping (WOC)

Ag, Ys, Sx

CD4

3

0.35

47b

Thornton, S.
Krikorian,
R.
Krikorian,
R.

87
1
14
7
14
7

Ag, Rc, Ys, Sx
Ag, Rc, Ys,
SES, ARV, Sx
Ag, Rc, Ys,
SES, ARV, Sx
Ag, Rc, Ad,
SES, ARV,
SES, Ad, Sx

CD4

44a

97
14
7
14
7
14
7
10
0
14
7
14
7

Positive Coping (IRM)

43

Ball, J.
BakkeFriedland
BakkeFriedland
Koopman,
C.
Koopman,
C.
Koopman,
C.
Thomason,
B.

1995

56

Positive Coping (WOC)

Ag, Ys, Sx

CD4

3

0.535

48a

Anderson, E.

2000

98

Positive Coping (LOT)

Ag, Rc, SES, Sx

CD4

3

0.073

48b

Anderson, E.

2000

Positive Coping (PLT)

Ag, Rc, SES, Sx

CD4

3

0.026

49a

Vassend, O.

1997

Positive Coping (WCCL)

Ag, Ys,Sx

CD4

2

0.16

48b

Vassend, O.

1997

Positive Coping (WCCL)

Ag, Ys,Sx

CD4

2

0.12

48c

Vassend, O.

1997

Positive Coping (WCCL)

Ag, Ys,Sx

CD4

2

0.13

48d

Vassend, O.

1997

Positive Coping (WCCL)

Ag, Ys,Sx

CD4

2

0.03

48e

Vassend, O.

1997

Positive Coping (WCCL)

Ag, Ys,Sx

CD4

2

0.12

48f

Vassend, O.

1997

Positive Coping (WCCL)

Ag, Ys,Sx

CD4

2

-0.07

48g

Vassend, O.

1997

Positive Coping (WCCL)

Ag, Ys,Sx

CD4

2

0.27

48h

Vassend, O.

1997

Positive Coping (WCCL)

Ag, Ys,Sx

CD4

2

0.12

48i

Vassend, O.

1997

98
10
4
10
4
10
4
10
4
10
4
10
4
10
4
10
4
10
4

Negative Coping (WCCL)

CD4

2

-0.11

50a

Grassi, L.

1999

73

Positive Coping (IBQ)

CD4

3

-0.3

59b

Grassi, L.

1999

73

Passive Coping (IBQ)

Ag, Ys,Sx
Ag, TT, Ys, Sx,
Or
Ag, TT, Ys, Sx,
Or

CD4

3

-0.27

41a
41b
42a
42b
42c

47a

2000
2000
1996

Passive Coping (COPE)
Passive Coping (COPE)
Negative Coping (COPE)
Positive Coping (WOC)
Positive Coping (IronsonWoods)
Positive Coping (IronsonWoods)

CD4

4

0.12
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51

Ullrich, P.

2003

73

Passive Coping (CT)

52

Hobbs, M.

2010

Positive Coping (SWB)

53

Rice, E.

2009

54

Biggar, H.
Kalichman,
S.

1999

82
19
6
20
5
24
1

55

2002

Ag, SES, Or
Ag, Rc, Ad,
SES, ARV, Or
Ag, Rc, Ys,
SES, Sx

Positive Coping (DOS)
Positive Coping (LOT)

Ag
Ag, Rc, Ys,
SES, Sx, Or

Positive Coping (PTA)

CD4

3

0.34

CD4

4

0.139

CD4

3

0.233

CD4

2

-0.14

Viral Load

2

0.43

Covariates: Ag = Age, Rc = Race, TT = Transmission Type, YS = Year Since Diagnosis, Ad = Adherence, ARV = Usage of
ARV’s ,SES = socio-economic status, Sx = Sex, Or = Sexual Orientation

Meta-Analysis Personality Studies
Adverse psychosocial
factor (measurement)

#

First
Author

1a

Ironson, G.

2008

104

Neuroticism

1b

Ironson, G.

2008

104

Neuroticism

1c

Ironson, G.

2008

104

Extraversion

1d

Ironson, G.

2008

104

Extraversion

1e

Ironson, G.

2008

104

Openness

1f

Ironson, G.

2008

104

Openness

1g

Ironson, G.

2008

104

Agreeableness

1h

Ironson, G.

2008

104

Agreeableness

1i

Ironson, G.

2008

104

Conscientiousness

1j

Ironson, G.
Thornton,
S.
O'Cleirigh,
C.
O'Cleirigh,
C.

2008

104

Conscientiousness

2000

147

Neuroticism

2007

119

Conscientiousness

2007

119

Conscientiousness

2009

112

Neuroticism

2007

258

2000

2
3a
3b
4

7

Lockenhoff
Johnson,
M.
Thornton,
S.
Vassend,
O.

8a

Millner, V.

5
6

Year

N

Covariates
Ag, Rc, Ad, SES,
ARV, Sx
Ag, Rc, Ad, SES,
ARV, Sx
Ag, Rc, Ad, SES,
ARV, Sx
Ag, Rc, Ad, SES,
ARV, Sx
Ag, Rc, Ad, SES,
ARV, Sx
Ag, Rc, Ad, SES,
ARV, Sx
Ag, Rc, Ad, SES,
ARV, Sx
Ag, Rc, Ad, SES,
ARV, Sx
Ag, Rc, Ad, SES,
ARV, Sx
Ag, Rc, Ad, SES,
ARV, Sx
Ag, SES, ARV
Ag, Rc, Ad, SES,
ARV, Sx, Or
Ag, Rc, Ad, SES,
ARV, Sx, Or

Quality
Score (0-4)

Effect
Size (r )

CD4

3

-0.028

Viral Load

3

0.001

CD4

3

0.045

Viral Load

3

-0.03

CD4

3

0.053

Viral Load

3

-0.025

CD4

3

0

Viral Load

3

0.009

CD4

3

0.02

Viral Load

3

0.015

CD4

3

0

CD4

3

0.196

Viral Load

3

-0.213

Outcome

CD4

3

0.2

Neuroticism

Ag,Sx
Ag, Rc, Ad, SES,
ARV , Sx

CD4

3

0.08

147

Neuroticism

Ag, SES, ARV

CD4

3

0

1997

107

Neuroticism

Ag, SES

CD4

2

0.097

1998

76

Neuroticism

Ag

CD4

3

0.03

8b

Millner, V.

1998

76

Extraversion

Ag

CD4

3

0.114

8c

Millner, V.

1998

76

Openness

Ag

CD4

3

0.031

8d

Millner, V.

1998

76

Agreeableness

Ag

CD4

3

0.291

8e

Millner, V.

1998

76

Agreeableness

Ag

CD4

3

0.107

8f

Millner, V.

1998

76

Agreeableness

Ag

CD4

3

0.161
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8g

Millner, V.

1998

76

Agreeableness

Ag

CD4

3

0.328

8h

Millner, V.

1998

76

Agreeableness

Ag

CD4

3

0.121

8i

Millner, V.

1998

76

Agreeableness

Ag

CD4

3

0.154

8j

Millner, V.

1998

76

Agreeableness

Ag

CD4

3

0.227

8k

Millner, V.

1998

76

Conscientiousness

Ag

CD4

3

0.224

8l

Millner, V.

1998

76

Conscientiousness

Ag

CD4

3

0.02

8m

Millner, V.

1998

76

Conscientiousness

Ag

CD4

3

0.233

8n

Millner, V.

1998

76

Conscientiousness

Ag

CD4

3

0.04

8o

Millner, V.

1998

76

Conscientiousness

Ag

CD4

3

0.333

8p

Millner, V.

1998

76

Conscientiousness

Ag

CD4

3

0.05

8q

Millner, V.

1998

76

Extraversion

Ag

CD4

3

0.138

8r

Millner, V.

1998

76

Openness

CD4

3

0.188

9a

Ironson, G.

2005

56

Conscientiousness

CD4

3

0.269

9b

2005

56

Conscientiousness

Viral Load

3

-0.284

10

Ironson, G.
Bottonari,
K.

2005

24

Neuroticism

Ag
Ag, Rc, Ad, SES,
ARV, Sex
Ag, Rc, Ad, SES,
ARV, Sex
Ag, Rc, TT, SES,
Sx, Or

CD4

2

-0.131

11a

Erlen, J.

2011

211

Neuroticism

Ag, Rc, Sx

CD4

4

0.234

11b

Erlen, J.

2011

211

Extraversion

Ag, Rc, Sx

CD4

4

-0.306

11c

Erlen, J.

2011

211

Openness

Ag, Rc, Sx

CD4

4

0.26

11d

Erlen, J.

2011

211

Agreeableness

Ag, Rc, Sx

CD4

4

-0.07

11e

2011

211

Conscientiousness

Ag, Rc, Sx

CD4

4

-0.157

2007

104

Neuroticism

Ag, Ys, Sx

CD4

2

0.15

12b

Erlen, J.
Vassend,
O.
Vassend,
O.

2007

104

Extraversion

Ag, Ys, Sx

CD4

2

-0.27

13

Ullrich, P.

2003

73

Neuroticism

Ag, SES, Or

CD4

3

-0.072

12a

Covariates: Ag = Age, Rc = Race, TT = Transmission Type, YS = Year Since Diagnosis, Ad = Adherence, ARV = Usage of
ARV’s, SES = socio-economic status, Sx = Sex, Or = Sexual Orientation

Meta-Analysis Social Support Studies
Quality
Score
(0-4)

Effect
Size (r)

#

First Author

Year

N

Adverse psychosocial factor
(measurement)

Covariates

Outcome

1a

Thornton, S.

2000

147

Functional Support (ISEL)

Ag, SES, ARV

3

0.269

1b

Thornton, S.

2000

147

Functional Support (ISEL)

Ag, SES, ARV

CD4
Viral
Load

3

0.162

2a

Cole, S.

2003

54

Functional Support (SI)

CD4

3

0.57

2b

Cole, S.

2003

54

Functional Support (SI)

Ag, Rc, SES, Or
Ag, Rc, SES, Or,
ARV

3

-0.61

2c

Cole, S.

2003

54

Structural Support (SI)

Ag, Rc, SES, Or

3

0.68

2d

Cole, S.

2003

54

Structural Support (SI)

Ag, Rc, SES, Or

3

0.75

2e

Cole, S.
Eisenberger,
N.
Eisenberger,
N.

2003

54

Structural Support (SI)

Ag, Rc, SES, Or

CD4
Viral
Load
Viral
Load
Viral
Load

3

0.58

2003

61

Structural Support (NSSQ)

Ag, Rc, SES, Sx

CD4

4

-0.17

2003

61

Structural Support (NSSQ)

Ag, Rc, SES, Sx

CD4

4

-0.15

3a
3b
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3e

Eisenberger,
N.
Eisenberger,
N.
Eisenberger,
N.

4a

Ironson, G.

2005

160

Functional Support (ESSI)

4b

Ironson, G.

2005

160

5a

Burgoyne, R

2005

65

5b

Burgoyne, R

2005

6a

Young, J.

2004

6b

Young, J.

2004

65
373
6
373
6

Functional Support (ESSI)
Functional Support
(MOSSSS)
Functional Support
(MOSSSS)

Structural Support (PSP)

ARV, Sx
Ag, Rc, SES,
ARV, Sx
Ag, Rc, SES,
ARV, Sx

7a

Persson, L.

2002

64

Structural Support (PFC)

7b

Persson, L.

2002

64

8

Thornton, S.

2000

147

3c
3d

2003

61

Structural Support (NSSQ)

Ag, Rc, SES, Sx

CD4

4

-0.32

2003

61

Structural Support (NSSQ)

Ag, Rc, SES, Sx

CD4

4

-0.13

2003

61

Structural Support (NSSQ)

Ag, Rc, SES, Sx
Ag, Rc, Ad,
SES, ARV, Sx
Ag, Rc, Ad,
SES, ARV, Sx

CD4

4

-0.07

CD4
Viral
Load

3

0

3

0

ARV, Sx

CD4
Viral
Load

2

0.287

2

0.326

Structural Support (PSP)

CD4
Viral
Load

3

0.038

3

0.016

Ag

CD4

3

0.06

Structural Support (PSP)

Ag

CD4

3

0.01

Functional Support (ISEL)

Ag, SES, ARV

CD4

3

0

9

Patterson, T.

1996

414

Functional Support (SSQ)

Ag, Rc, SES

CD4

2

0

10

Theorell,T.

1995

51

Functional Support (SNSQ)

Ag, SES, Or

CD4

2

0.575

11a

Igreja, I.

2000

39

Functional Support (ISEL)

Ag, SES, Or

CD4

3

-0.114

11b

Igreja, I.

2000

39

Functional Support (SSHI)

Ag, SES, Or

CD4

3

-0.13

12a

Hobbs, M.

2010

82

Functional Support (SSQ)

Ag,Or

CD4

4

0.044

12b

Hobbs, M.

2010

82

Functional Support (SSQ)

CD4

4

0.045

13

Leserman, J.

1999

82

Functional Support (SBSSQ)

CD4

4

0.4

14

Leserman, J.

2002

82

Functional Support (SBSSQ)

CD4

4

0.227

15

Solano, L.

2002

200

Ag,Or
Ag, Rc, Ad,
ARV, Or
Ag, Rc, Ad,
ARV, Or
Ag, TT, Ys, Sx,
Or

CD4

3

0.217

16

Vassend, O.

1998

62

Functional Support (WCCL)

CD4

3

-0.175

17

Ashton, E.

2005

65

Functional Support (SSI)

CD4

4

-0.08

18

Leserman, J.

2000

82

Functional Support (BSSQ)

CD4

4

0.217

19a

Strachan, E.

2007

373

Structural Support (KS)

CD4

3

0.019

19b

Strachan, E.

2007

373

Structural Support (KS)

CD4

3

0.041

20

Ironson, G.

2006

100

Functional Support (ESSI)

CD4

4

0.184

21a

Fekete, E.

2009

102

Functional Support (SSI)

CD4

4

0.206

21b

Fekete, E.

2009

102

Functional Support (SSI)

CD4

4

-0.179

21c

Fekete, E.

2009

102

Structural Support (SSI)

Viral
Load

4

-0.247

21d

Fekete, E.

2009

102

Structural Support (SSI)

Viral
Load

4

0.145

Functional Support (SSS)

Ag, Ys, Or
Ag, Rc, Ad,
SES, ARV, Sx,
Or
Ag, Rc, Ys, Ad,
ARV, Or
Ag, Rc, ARV,
Sx, Or
Ag, Rc, ARV,
Sx, Or
Ag, Rc, TT, Ys,
Ad, SES, ARV,
Sx, Or
Ag, Rc, TT, Ys,
Ad, SES, ARV,
Sx, Or
Ag, Rc, TT, Ys,
Ad, SES, ARV,
Sx, Or
Ag, Rc, TT, Ys,
Ad, SES, ARV,
Sx, Or
Ag, Rc, TT, Ys,
Ad, SES, ARV,
Sx, Or
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Functional Support (PES)

Ag, Rc, Ad,
ARV, Or
Ag, Rc, Ad,
ARV, Or
Ag, Rc, Ad,
ARV, Or
Ag, Rc, Ad,
ARV, Or
Ag, Rc, Ad,
ARV, Or
Ag, Rc, Ad,
ARV, Or
Ag, Rc, Ad,
ARV, Or
Ag, TT, Ys, Ad,
SES, ARV,Sx
Ag, TT, Ys, Ad,
SES, ARV,Sx

78

Structural Support (MSPSS)

2008

78

2008

Robbins, M.

25b
25c

22a

Miller, G.

1997

205

Structural Support (SSI)

CD4

4

-0.12

22b

Miller, G.

1997

205

Structural Support (SSI)

CD4

4

-0.03

22c

Miller, G.

1997

205

Structural Support (SSI)

CD4

4

0.02

22d

Miller, G.

1997

205

Structural Support (SSI)

CD4

4

0.1

22e

Miller, G.

1997

205

Structural Support (SSI)

CD4

4

0.11

22f

Miller, G.

1997

205

Structural Support (SSI)

CD4

4

0.09

22g

MIller, G.

1997

205

Structural Support (UCLAL)

CD4

4

0.18

23a

Cohen, M.

2007

56

Functional Support (PES)

CD4
Viral
Load

2

0.31

23b

2007

56

2008

24c

Cohen, M.
Oppenheimer,
M.
Oppenheimer,
M.
Oppenheimer,
M.

2

-0.3

Rc, TT, SES, Sx

CD4

3

0.681

Structural Support (MSPSS)

Rc, TT, SES, Sx

CD4

3

0.023

78

Structural Support (MSPSS)

Rc, TT, SES, Sx

CD4

3

0.201

25a

2003

48

Structural Support (SSQ)

Ag, SES

CD4

3

0.43

Robbins, M.

2003

20

Structural Support (SSQ)

Ag, SES

CD4

3

0.016

Robbins, M.

2003

20

Structural Support (SSQ)

Ag, SES

CD4

3

0.065

25d

Robbins, M.

2003

15

Structural Support (SFSR)

Ag, SES

CD4

3

0.038

25e

Robbins, M.

2003

20

Structural Support (SFSR)

Ag, SES

CD4

3

0.057

24a
24b

25f

Robbins, M.

2003

48

Functional Support (SSQ)

Ag, SES

CD4

3

0.255

25g

Robbins, M.

2003

26

Functional Support (SSQ)

Ag, SES

CD4

3

-0.016

25h

Robbins, M.

2003

12

Functional Support (SSQ)

Ag, SES

CD4

3

0.183

26a

LeGrand, S.

2010

435

Ag, Rc, SES

CD4

4

0.1

26b

LeGrand, S.

2010

435

Ag, Rc, SES

CD4

4

0.055

26c

2010

435

Ag, Rc, SES

CD4

4

0.01

1999

97

Functional Support (PSS)

Ag, Rc, SES, Or

CD4

3

-0.023

1999

97

Functional Support (PSS)

Ag, Rc, SES, Or

CD4

3

-0.148

27c

LeGrand, S.
BakkeFriedland
BakkeFriedland
BakkeFriedland

Structural Support (IAS)
Functional Support
(MOSSSS)
Functional Support
(MOSSSS)

1999

97

Ag, Rc, SES, Or

CD4

3

0.338

28a

Tang, H.

2002

410

Ag, SES, Sx

CD4

4

-0.06

28b

Tang, H.

2002

410

Ag, SES, Sx

CD4

4

0.07

28c

Tang, H.

2002

410

Ag, SES, Sx

CD4

4

0.093

28d

Tang, H.

2002

410

Functional Support (PSS)
Functional Support
(MOSSSS)
Functional Support
(MOSSSS)
Functional Support
(MOSSSS)
Functional Support
(MOSSSS)

Ag, SES, Sx

CD4

4

0.07

29a

Burgoyne,R.

2000

114

Ag, SES, Sx

CD4

3

0.296

29b

Burgoyne,R.

2000

114

Ag, SES, Sx

CD4

3

-0.174

29c

Burgoyne,R.

2000

114

Ag, SES, Sx

CD4

3

-0.089

29d

Burgoyne,R.

2000

114

Ag, SES, Sx

CD4

3

-0.041

27a
27b

Structural Support (MOSSSS)
Functional Support
(MOSSSS)
Functional Support
(MOSSSS)
Functional Support
(MOSSSS)
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29e

Burgoyne,R.

2000

114

Functional Support
(MOSSSS)

30

Brashers, D.

2002

147

Structural Support (ACT)

31

Koopman, C.

2000

147

32a

Igreja, I.

1997

32b

Igreja, I.

32c

Igreja, I.

32d

Ag, SES, Sx

CD4

3

-0.081

CD4

2

-0.012

Structural Support (SSI)

Rcm Ys, Sx, Or
Ag, Rc, Ys, SES,
Sx, Or

CD4

4

-0.102

88

Structural Support (SSHI)

Ag, SES, Or

CD4

4

-0.067

1997

88

Structural Support (SSHI)

Ag, SES, Or

CD4

4

-0.112

1997

88

Functional Support (SSHI)

Ag, SES, Or

CD4

4

-0.114

Igreja, I.

1997

88

Ag, SES, Or

CD4

4

-0.13

33

Burgoyne, R.

2005

34

Functional Support (SSHI)
Functional Support
(MOSSSS)

CD4

3

0.199

34

Nair, K.

2009

120

Functional Support (MPSS)

CD4

3

0.022

35a

Alemu, H.

2012

882

Functional Support (NSSQ)

CD4

3

0.068

35b

Alemu, H.

2012

569

Functional Support (NSSQ)

ARV, Sx
Ag, Rc, Ys, SES,
ARV, Sx
Ag, Ad, SES,
ARV, Sx
Ag, Ad, SES,
ARV, Sx

CD4

3

0.08

36

Thomason, B.

1996

100

Functional Support (ISEL)

Ag, Rc, Ys,Sx

CD4

3

0.101

37

Vassend, O.

1997

104

Functional Support (WCCL)

CD4

3

0

38

Grassi, L.

1999

73

Structural Support (IBQ)

Ag, SES
Ag, TT, Ys, Sx,
Or

CD4

3

0.04

39a

Ullrich, P.

2003

73

Functional Support (SSQ)

Ag, SES, Or

CD4

3

0.225

39b

2003

73

Functional Support (SCS)

3

-0.025

2011

132

Functional Support (DAS)

CD4

4

0.048

2011

132

Functional Support (DAS)

CD4

4

-0.07

2011

132

Functional Support (CTS)

CD4

4

-0.023

2011

132

Functional Support (CTS)

CD4

4

-0.108

2011

132

Functional Support (SSQ)

CD4

4

0.052

2011

132

Functional Support (SSQ)

CD4

4

0.2

2011

132

Functional Support (SSQ)

CD4

4

-0.243

2011

132

Functional Support (SSQ)

CD4

4

-0.01

41

Lucero, T.

1999

69

Functional Support (ISEL)

Ag, SES, Or
Ag, Rc, TT, Ad,
SES, ARV, Or
Ag, Rc, TT, Ad,
SES, ARV, Or
Ag, Rc, TT, Ad,
SES, ARV, Or
Ag, Rc, TT, Ad,
SES, ARV, Or
Ag, Rc, TT, Ad,
SES, ARV, Or
Ag, Rc, TT, Ad,
SES, ARV, Or
Ag, Rc, TT, Ad,
SES, ARV, Or
Ag, Rc, TT, Ad,
SES, ARV, Or
Ag, Rc, TT,
ARV, Sx, Or

CD4

40h

Ullrich, P.
DelaGarzaMe
rcer
DelaGarzaMe
rcer
DelaGarzarM
erce
DelaGarzaMe
rcer
DelaGarzaMe
rcer
DelaGarzaMe
rcer
DelaGarzaMe
rcer
DelaGarzaMe
rcer

CD4

4

-0.144

42a

Dutile, R.

2004

84

Functional Support (SPS)

Ag, Sx

CD4

3

-0.23

42b

Dutile, R.

2004

84

Functional Support (SPS)

Ag, Sx

CD4

3

-0.41

42c

Dutile, R.

2004

84

Functional Support (SPS)

Ag, Sx

CD4

3

-0.27

42d

Dutile, R.

2004

84

Functional Support (SPS)

Ag, Sx

CD4

3

-0.15

42e

Dutile, R.

2004

84

Functional Support (SPS)

Ag, Sx

CD4

3

-0.3

42f

Dutile, R.

2004

84

Functional Support (SPS)

Ag, Sx

3

-0.21

42g

Dutile, R.

2004

84

Functional Support (SPS)

Ag, Sx

3

0.06

42h

Dutile, R.

2004

84

Functional Support (SPS)

Ag, Sx

3

0.23

42i

Dutile, R.

2004

84

Functional Support (SPS)

Ag, Sx

3

0.08

42j

Dutile, R.

2004

84

Functional Support (SPS)

Ag, Sx

CD4
Viral
Load
Viral
Load
Viral
Load
Viral
Load

3

-0.09

40a
40b
40c
40d
40e
40f
40g
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42k

Dutile, R.

2004

84

Functional Support (SPS)

Ag, Sx

42l

Dutile, R.

2004

84

Functional Support (SPS)

Ag, Sx

Viral
Load
Viral
Load

3

0.01

3

0.04

Covariates: Ag = Age, Rc = Race, TT = Transmission Type, YS = Year Since Diagnosis, Ad = Adherence, ARV = Usage of
ARV’s ,SES = socio-economic status, Sx = Sex, Or = Sexual Orientation
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Appendix B
Coping Egger’s Funnel Plot
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Personality Egger’s Funnel Plot
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Social Support Egger’s Funnel Plot
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Appendix C
Coding Manual and Coding Forms for Meta-Analysis of Psychosocial Effects
A. Study Level Coding Manual
1. Bibliographical Reference
a. Study ID Number
b. Publication Year
c. Quality Assessment Score (0-4)
2. Sample Descriptors/Covariates
a. Sample Size
b. Cohort Nation
c. Covariates (1 = Yes, 2 = No)
i. Age
ii. Race
iii. Transmission Type
iv. Years since Diagnosis
v. Adherence to ARV’s
vi. Usage of ARV’s
vii. SES
viii. Sex
ix. Sexual Orientation
3. Research Design Descriptors
a. Follow Up Study (1 = Yes, 2 = No)
b. Measure (Scale Used)
c. Outcome Variable (1 = CD4, 2 = Viral Load)
d. Independent Variable
i. Social Support Data Set
1. Structural Support = 1
2. Functional Support = 2
ii. Personality Data Set (1-5)
1. Neuroticism = 1
2. Extraversion = 2
3. Openness to Experience = 3
4. Agreeableness = 4
5. Conscientiousness = 5
iii. Coping Data Set (1-3)
1. Positive Coping = 1
2. Passive Coping = 2
3. Negative Coping = 3
B. Effect Size Level Coding Manual
a. Effect Size (Pearson’s r)
b. Weighted effect size
c. Standard Error
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